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Systemic amyloid A (AA) amyloidosis is an increasingly important cause of 
morbidity and mortality among captive cheetahs, yet wild cheetahs are virtually 
unaffected, suggesting the phenomenon is a result of the captive condition. The self-
aggregating AA protein responsible for this disease, is a byproduct of serum amyloid 
A (SAA) protein degradation, an acute phase protein highly upregulated during 
inflammation. The objective of this study was to identify the relationship between 
genetics, stress, and inflammation with serum concentrations of the SAA protein and 
the incidence of AA amyloidosis in captive cheetahs. Fecal and serum samples 
collected from cheetahs held at the Smithsonian (NZP-SCBI) and Cheetah 
  
Conservation Fund (CCF) facilities, as well as wild, free-ranging cheetahs, were 
examined. Enzyme-linked immunosorbent assays were used to measure SAA protein 
and proinflammatory cytokine concentrations in serum samples and cortisol 
concentrations in feces. Additionally, cheetahs were genotyped for the SAA1A-97delG 
single nucleotide polymorphism (SNP) in the promoter region of the SAA1 gene. 
This study was the first to demonstrate that serum concentrations of the SAA protein 
in cheetahs are affected by the SAA1A-97delG SNP (P=0.0453). However, the high 
prevalence of AA amyloidosis observed among captive cheetahs is not attributable to 
genetic differences at this locus, but rather appears to be related to stress and/or 
inflammation, as captive cheetahs at NZP-SCBI have significantly higher SAA 
protein concentrations in serum compared to captive cheetahs at CCF, regardless of 
genotype (P=0.0003). Captive cheetahs at NZP-SCBI show levels of stress (fecal 
cortisol concentrations) greater than their captive counterparts at CCF in Namibia. 
Interestingly, wild cheetahs and captive cheetahs at CCF in Namibia had significantly 
higher proinflammatory cytokine concentrations (TNF-α and IL-1β) in serum 
compared to cheetahs at NZP-SCBI (P<0.0001). It is possible that chronic stress may 
be suppressing the production of proinflammatory cytokines in the NZP-SCBI 
cheetah population. Controlling the currently high SAA protein concentrations 
associated with AA amyloidosis is the best strategy to decreasing the diseases 
prevalence among captive cheetahs. Promoting management practices that reduce 
stress could help re-establish proper immune system homeostasis and mitigate the 
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Chapter 1: Review of literature, research objective and 
hypotheses 
 
Current status of the cheetah 
The cheetah, Acinonyx jubatus, is a member of the family Felidae, and ranges 
historically from Africa into Asia (Durant et al. 2008). Unfortunately, wild 
populations of cheetah are declining due to habitat loss and fragmentation, a depleted 
prey base, conflict with farmers and ranchers, exportation into the pet trade, as well as 
interspecific competition with large predators such as lions and hyenas (Durant et al. 
2008). The wild population was recently estimated to be between 7,500 and 10,000 
individuals (Durant et al. 2008).  With the population in decline, cheetahs are listed as 
“vulnerable” on the IUCN Red List of Threatened SpeciesTM. At the end of 2012, the 
captive cheetah population was comprised of 1,661 individuals, among 250 facilities, 
in 44 countries (Marker 2013). Twenty-one percent of these captive animals are held 
and managed in North American facilities (Marker 2013).  
Captive cheetahs in North America are currently managed under a Species 
Survival Plan (SSP®). A major goal of the SSP® for captive cheetahs in North 
America is to create a self-sustaining population that no longer requires the 
importation of cheetahs from Africa. Currently, this goal is not being met. However 
there are multiple ways to increase captive population growth including: improving 
reproduction (increasing mating and pregnancy success) and decreasing mortality 
(improving juvenile mortality and litter survival rates, improvements to diet and 




requires rigorous captive population management and the implementation of a new 
approach to the captive breeding program. Consequently, representatives from North 
American facilities meet each year to make decisions on breeding recommendations 
and movement of animals within and between facilities based on genetics, fertility, 
behavior, age and health (Grisham et al. 2013).  
Aside from increasing mortality, diseases are a cause for concern to captive 
population managers because they affect behavior, inhibit the movement of animals 
between facilities, and impact the ability to anesthetize an individual for any required 
or special medical procedures, including assisted reproductive technologies. 
Diseases among captive cheetahs 
Diseases among cheetahs in captivity are exceedingly common, limiting their 
lifespan (Munson 1993), yet despite the high prevalence of many diseases observed in 
captive cheetahs in both North America and South Africa, wild cheetahs are virtually 
unaffected (Munson et al. 2005).  This disparity suggests the phenomenon is not 
simply due to the low genetic diversity observed among both wild and captive 
cheetahs (Castro-Prieto et al. 2011, Drake et al. 2004, O’Brien et al. 1983, O’Brien et 
al. 1985, Yuhki and O’Brien 1990), but rather a result of the captive condition. 
Adrenal cortical hyperplasia is a condition that has been commonly documented 
among captive cheetahs (Bolton and Munson 1999, Munson et al. 1999, Munson et 
al. 2005, Terio et al. 2004), thus it has been speculated that stress due to the captive 





Stress can be defined as a physiological or psychological state in which 
homeostasis is, or perceived to be, threatened (Chrousos 2009, Dhabhar 2009, 
Elenkov and Chrousos 1999). The biological reaction (or purpose) of acute stress is to 
divert energy resources to muscles while inhibiting energy storage, to stimulate 
immune function through the mobilization of immune cells from storage to peripheral 
tissues, to inhibit reproduction, to decrease feeding and appetite, to sharpen cognition, 
and to increase water retention (in cases of blood loss), all in an effort to increase the 
probability of short-term survival (Sapolski et al. 2000). The major effectors 
mediating homeostasis produced in the central nervous system are arginine 
vasopressin (AVP) and corticotropin-releasing hormone (CRH) (Chrousos 2009, 
Elenkov and Chrousos 1999); peripheral effectors also mediating homeostasis include 
catecholamines and glucocorticoids (GCs) (Chrousos 2009, Dhabhar 2009, Elenkov 
and Chrousos 1999).  
Stress activates the sympathetic nervous system which stimulates the release 
of catecholamines (epinephrine and norepinephrine; E and NE) from the adrenal 
medulla. Stress also results in activation of the hypothalamic-pituitary-adrenal (HPA) 
axis by innervating neurons in the paraventricular nucleus of the hypothalamus to 
secrete CRH, which travels through the portal vein system to activate corticotropic 
cells in the anterior pituitary, which in turn release adrenocorticotropic hormone 
(ACTH) into circulation. The ACTH signal is received by cells of the adrenal cortex, 
stimulating the production and release of GCs, such as cortisol and corticosterone. 




later followed by GCs released from the adrenal gland (Chrousos 1995, Chrousos 
2009, Dhabhar 2009, Elenkov and Chrousos 1999, Sapolski et al. 2000). 
Psychological stressors can trigger the release of proinflammatory cytokines 
before any rise in GCs is detected (Dhabhar 2009, Sapolski et al. 2000). Specifically, 
catecholamines have been shown to stimulate the release of the proinflammatory 
cytokine IL-6 from immune cells (Chrousos 1995, Chrousos 2009). Conversely, 
proinflammatory cytokines are known to stimulate the stress system (HPA axis 
activation), causing the release of CRH (Baumann and Gauldie 1994, Chrousos 2009, 
Elenkov and Chrousos 1999, Sapolski et al. 2000). Peripheral CRH has been known 
to have proinflammatory actions (Elenkov and Chrousos 1999). Studies in mice have 
shown that the proinflammatory cytokine IL-6 is essential for activation of the HPA 
axis during immune challenges in the absence of CRH (Bethin et al. 2000); 
supporting evidence includes the presence of IL-6 receptors on the surface of pituitary 
corticotrophs and adrenocortical cells (Bethin et al. 2000). The same study also found 
the relative contribution of IL-6 for modulation of the adrenal response to stress 
greater in female mice, suggesting differences between sexes when it comes to the 
induction of the HPA axis in response to inflammation (Bethin et al. 2000). 
Activation of the HPA axis by proinflammatory cytokines plays an important 
role in the negative feedback mechanism that controls systemic proinflammatory 
cytokine concentrations from becoming detrimental to the organism: both 
catecholamines and GCs suppress the secretion of most proinflammatory cytokines 




Additionally, production of the anti-inflammatory cytokine IL-10 is upregulated by 
GCs (Elenkov and Chrousos 1999).  
Stress among captive cheetahs 
It has been widely accepted that captivity can impose psychological stress on 
many animal species. Measuring glucocorticoids in fecal samples across time can be 
a valuable, non-invasive tool for measuring stress in many animals, including 
cheetahs (Keay et al. 2006). Cheetahs defecate approximately once per day, therefore 
any diurnal fluctuations in cortisol due to circadian secretory patterns are attenuated 
in feces (Keay et al. 2006). 
There is both functional (hypercortisolemia) and morphological evidence 
(adrenal hyperplasia/hypertrophy) for chronic stress among captive cheetahs, at levels 
much greater than their wild counterparts (Bolton and Munson 1999, Kӧster et al. 
2007, Munson et al. 1999, Munson et al. 2005, Terio et al. 2004). Similarly, in 
captivity, when cheetahs are moved or housed on-exhibit, they tend to show greater 
levels of stress (higher GC concentrations in feces) than when moved or housed off-
exhibit (Terio et al. 2004, Wells et al. 2004), and the increases observed after 
movement can persist for months (Wells et al. 2004). There is also greater daily 
variation in the GC concentrations of feces observed when cheetahs are moved on-
exhibit (Wells et al. 2004). Evidence of stress (elevated cortisol and/or behavior) 
being linked to anestrous in captive cheetahs (downregulation of the reproductive 
system) has also been demonstrated (Jurke et al. 1997, Wielebnowski et al. 2002). 
Hence, it appears there is a clear association between the captive environment and 




Stress-related hypersecretion of the proinflammatory cytokine IL-6, in 
addition to hypercortisolism, may result in the chronic upregulation of the acute phase 
response (Chrousos 2009), contributing to the increase in disease and mortality 
observed in the captive cheetah population. 
The acute phase response 
The acute phase response (APR) is a systemic reaction that occurs early 
during inflammation, initiated by cells of the innate immune system in response to 
invading pathogens, tissue damage, and associated activation signals. Macrophages 
resident in affected tissues and monocytes in the blood are the immune cells primarily 
responsible for the initiation of the APR (Baumann and Gauldie 1994, Paltrinieri 
2008). The liver is one of the primary targets for systemic inflammatory mediators 
(Baumann and Gauldie 1994, Jensen and Whitehead 1998, Paltrinieri 2008); it is the 
location of acute phase protein (APP) production (Baumann and Gauldie 1994, Cerón 
et al. 2005, Jensen and Whitehead 1998, Paltrinieri 2008). APPs, by definition, are 
proteins whose concentration in serum significantly increases or decreases during the 
APR. There is a high degree of similarity in the response patterns of several APPs to 
systemic inflammatory mediators during the APR across species (Baumann and 
Gauldie 1994, Cerón et al. 2005, Paltrinieri 2008), including C-reactive protein 
(CRP), serum amyloid A protein (SAA), alpha-1-acid glycoprotein (AGP), 
ceruloplasmin, haptoglobin, and albumin. The systemic inflammatory mediators 
generally responsible for the upregulation of CRP, SAA, and AGP production during 
the APR are the IL-1 type cytokines, such as IL-1β and TNF-α (Baumann and 




2008). Additionally, the actions of the IL-1 type cytokines on the production of APPs 
are often synergistically enhanced in the presence of IL-6 (Baumann and Gauldie 
1994, Cerón et al. 2005, Jensen and Whitehead 1998).  
Serum amyloid A: a major acute phase protein in domestic cats 
The major APPs that have been identified to date in the domestic cat are SAA 
and AGP (Cerón et al. 2005, Kajikawa et al. 1999, Paltrinieri 2008); CRP is not a 
highly reactive APR in domestic cats (Kajikawa et al. 1999). In humans, the 
concentration of SAA found in circulation bound to high-density lipoproteins 
increases as much as 1000-fold within 24-48 hours of the initiation of inflammation 
(Marhaug and Dowton 1994). The increase in SAA observed in domestic cats during 
the APR, approximately a 10-100 fold increase, is lower in magnitude compared to 
humans and other species, but still represents a major APP in this species (Cerón et 
al. 2005, Giordano et al. 2004, Kajikawa et al. 1999), and multiple studies have 
shown that the SAA concentrations in sick cats is significantly higher than the SAA 
concentrations in healthy cats (Table 1.1). A pattern of increased SAA concentrations 
among older domestic cats has also been reported (Campbell et al. 2004, Kann et al. 
2012). The increase in SAA concentration with age appears to be associated with a 
decrease in white blood cells, peripheral blood lymphocytes and circulating 
eosinophils, and fewer CD4+ T cells among older domestic cats (Campbell et al 
2004). 
The SAA protein is well conserved throughout evolution, indicating an 
important biological function (Marhaug and Dowton 1994). Possible roles of SAA 









Table 1.1. Previous literature investigating serum amyloid A (SAA) concentrations in 





Mean ± SEM 
Method Author 
Healthy 
(n = 26) 
0.14 ± 0.05 µg/ml ELISA* 
TIA^ 
Tamamoto et al. 2008 
Diseased 
(n = 263) 
7.52 ± UR µg/ml ELISA* 
TIA^ 
Tamamoto et al. 2008 
Healthy 
(n = 20) 
16.6 ± 2.55 µg/ml ELISA# Kajikawa et al. 1999 
Hospitalized 
(n = 20) 
150.1 ± 16.3 µg/ml ELISA# Kajikawa et al. 1999 
Healthy 
(n = 34) 
1.8 ± 2.3 µg/ml ELISA§ Kann et al. 2012 
Sick 
(n = 32) 
16.0 ± 32.1 µg/ml ELISA§ Kann et al. 2012 
Healthy 
(n = 24) 
10.21 ± 1.70 µg/ml ELISA§ Giordano et al. 2004 
FCoV exposed 
(n = 7) 
7.92 ± 2.69 µg/ml ELISA§ Giordano et al. 2004 
FIP infected 
(n = 32) 
82.88 ± 8.88 µg/ml ELISA§ Giordano et al. 2004 
Healthy 
(n = 45) 
0.60 ± 0.16 µg/ml ELISA Sasaki et al. 2003 
Diseased 
(n = 312) 
33.65 ± 3.83 µg/ml ELISA Sasaki et al. 2003 
*BioSource Multispecies SAA ELISA kit, BioSource International, Inc., Camarillo, CA, 
U.S.A.  
^Turbidimetric immunoassay for human SAA, LZ-SAA, Eiken Chemical Co., Ltd. 
#Kajikawa, T., Furuta, A., Onishi, T., Sugii, S., 1996. Enzyme-linked immunosorbent assay 
for detection of feline serum amyloid A protein by use of immunological cross-reactivity of 
polyclonal anti-canine serum amyloid A protein antibody. J. Vet. Med. Sci. 58, 1141-1143. 








inflammation, involvement in lipid metabolism and transport, increasing cytokine 
production in monocytes and macrophages, and stimulating nitric oxide production in 
macrophages (Cerón et al. 2005, Jensen and Whitehead 1998, Tamamoto et al. 2012). 
In domestic cats, SAA appears to also play a protective role in inflamed tissue by 
scavenging for oxidized cholesterol, thereby preventing prolonged tissue damage 
(Paltrinieri 2008).  
Transcriptional regulation of the SAA gene 
The CCAAT-enhancer-binding proteins (C/EBPs) are primarily responsible 
for the regulation of SAA transcription (Ray and Ray 1994). Both C/EBPβ and 
C/EBPδ are newly synthesized under acute phase conditions, activated by 
phosphorylation, and induce transcription of the SAA gene in a dose-dependent 
manner (Ray and Ray 1994). The C/EBP binding site in the promoter of the human 
SAA gene is located within the 265bp region upstream of the transcription start site 
(Marhaug and Dowton 1994). Also located within this region is a binding site for the 
transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B 
cells) (Marhaug and Dowton 1994). The active form of NF-κB is a heterodimer, 
usually comprised of two proteins, p65 and p50 (Barnes and Karin 1997, Beg et al. 
1993).  
Without stimulation signaling, NF-κB is bound to IκBα or IκBβ in the 
cytoplasm of the cell and is prevented from entering the nucleus (Barnes and Karin 
1997, Beg et al. 1993). However, in the presence of stimulation from 
proinflammatory cytokines, such as TNF-α (Beg et al. 1993, Scheinman et al. 1995) 




κB, and get degraded (Barnes and Karin 1997, Beg et al. 1993). The unbound NF-κB 
enters the nucleus and binds to the promoter region of target genes associated with 
inflammatory and immune responses, such as SAA (Barnes and Karin 1997, Beg et al. 
1993). IL-1β, TNF-α, and IL-6 proinflammatory cytokines have all been shown to 
stimulate hepatic SAA production during the APR (Baumann and Gauldie 1994, 
Cerón et al. 2005, Jensen and Whitehead 1998, Marhaug and Dowton 1994, 
Paltrinieri 2008). 
In addition to proinflammatory target genes, NF-κB induces synthesis of 
IκBα, therefore the activity of NF-κB is self-regulated (Barnes and Karin 1997). 
Glucocorticoids also induce transcription of IκBα (Auphan et al. 1995, Barnes and 
Karin 1997, Scheinman et al. 1995). Multiple studies have shown that IκBα synthesis 
is increased in the presence of dexamethasone (DEX: a synthetic glucocorticoid), 
causing fast reassociation of NF-κB with IκBα, thus reducing the translocation of NF-
κB to the nucleus, even under cytokine stimulation (Auphan et al. 1995, Scheinman et 
al. 1995); this inhibitory effect of DEX is mediated through cytoplasmic 
glucocorticoid receptors (Auphan et al. 1995), with possible direct protein-protein 
interaction between the glucocorticoid receptor (GR) and NF-κB (Barnes and Karin 
1997). Therefore, activated GRs are involved in blocking transcription factors 
required for the expression of proinflammatory target genes (Chrousos 1995). It is 
widely accepted that the expression of many cytokines (including TNF-α, IL-1β, and 
IL-6) is inhibited by GCs (Baumann and Gauldie 1994, Chrousos 1995, Jensen and 




Contrastingly, there is a positive, synergistic effect of GCs with cytokines in 
the induction of SAA synthesis during the APR (Chrousos 1995, Dhabhar 2009, 
Marhaug and Dowton 1994). This effect is the result of the upregulation of cytokine 
receptors on the surface of hepatic cells by GCs (Baumann and Gauldie 1994, 
Wiegers and Reul 1998), increasing the sensitivity of the hepatic cells to cytokine 
stimulation (Baumann and Gauldie 1994, Paltrinieri 2008, Thorn and Whitehead 
2002, Wiegers and Reul 1998). During the APR, IL-1β and IL-6 can act on the 
pituitary-adrenal axis to stimulate production of ACTH, inducing the production of 
cortisol (Baumann and Gauldie 1994, Chrousos 2009, Elenkov and Chrousos 1999, 
Sapolski et al. 2000). Therefore, it appears GCs play a role in the systemic 
inflammatory response by increasing production of APPs during the APR. These 
effects, combined with the increased post-transcriptional stability of SAA mRNA due 
to the production of longer poly-A tails (Jensen and Whitehead 1998), contribute to 
the major increases in SAA concentration observed in serum during the APR. Higher 
SAA concentrations in serum were found to be positively correlated with prednisone 
treatment (a synthetic GC) in systemic lupus erythematosus patients compared to 
patients without treatment (Esmat et al. 2005). Unfortunately, this could mean that 
administering glucocorticoids as a therapy for diseases characterized with chronic 
inflammation may have an undesirable or even harmful effect resulting in higher 
serum SAA concentrations. Factors regulating SAA protein production in the liver are 








Amyloid A amyloidosis 
The SAA protein normally has a short half-life, approximately 90 minutes in 
normal serum (Marhaug and Dowton 1994). Therefore, the concentration of SAA in 
serum returns to normal following the termination of inflammation. In multiple 
species, including domestic cats, monocytes contribute to SAA degradation (Migita et 
al. 2001, Tamamoto et al. 2012); however, this is inhibited in the presence of the 
cytokines IL-1β and IFN-γ (Migita et al. 2001), and glucocorticoids (Tamamoto et al. 
2012). SAA itself can induce the expression and secretion of TNF-α and IL-1β from 
human macrophages through interactions with the TLR2 and TLR4 receptors (Niemi 
et al. 2011), contributing to its own persistence. Thus, chronic systemic inflammation 
can result in the persistent upregulation of SAA production, a decrease in SAA 
degradation, and an accumulation of SAA protein in the serum, providing evidence 
that it plays a role in amyloid A (AA) amyloidosis pathogenesis.  
The N-terminal region of the SAA protein is the precursor for the AA protein, 
the first 10-15 amino acid residues of which are amyloidogenic (Marhaug and 
Dowton 1994). In abundance, the AA protein polymerizes to form fibrils which are 
insoluble and deposit into the liver, kidney, spleen and other organs. As stated 
previously, in the presence of inflammation, SAA may be slowly or improperly 
degraded, leading to an accumulation of AA protein (Marhaug and Dowton 1994). It 
has been shown that SAA can also induce the secretion of cathepsin B from 
macrophages through direct activation of the P2X7 receptor (Niemi et al. 2011). This 
effect, considered together with evidence that cathepsin B is capable of degrading 




chronic inflammation may lead to the extracellular proteolytic processing of SAA 
into AA amyloidogenic fragments. Thus, AA amyloidosis is a disease induced by the 
over-accumulation and incomplete degradation of SAA and polymerization of AA 
protein into fibrils (Marhaug and Dowton 1994). Therefore, it is unsurprising that 
elevated SAA concentrations in serum have been found to correlate with AA 
amyloidosis, cancer and other inflammatory diseases in humans (Biran et al. 1986, 
Lachmann et al. 2007, Marhaug and Dowton 1994).  
Structure and expression of the cheetah SAA genes 
Four serum amyloid A protein genes (SAA1A, SAA1B, SAA3A, SAA3B) have 
been identified in the cheetah genome, yet these SAA proteins are monomorphic: all 
polymorphisms are observed in non-coding regions of the genes (Chen et al. 2012). 
This represents a decrease in polymorphisms in the cheetah SAA1 and SAA3 genes 
in comparison to human and mouse orthologs (Chen et al. 2012). Similar to other 
species, the SAA genes appear to be linked on the same chromosome due to the 
cosegregation of allelic haplotypes (Chen et al. 2012).  
The structure of the cheetah SAA1 genes show high similarity to the human 
SAA1 and mouse Saa1 genes (Zhang et al. 2008b). Transcriptional induction of the 
SAA1 gene in cheetahs by IL-1β and IL-6 is dependent on the presence of both 
C/EBPβ and NF-κB elements (Zhang et al. 2008b). Nucleotide sequences of C/EBPβ 
and NF-κB target sites are highly conserved between cheetah and human (Zhang et al. 
2008b). The NF-κB element in the promoter of the SAA1 gene in cheetahs cannot 
confer promoter activity alone, yet the C/EBPβ element retains partial promoter 




(2008b) identified two alleles for a polymorphism consisting of a single guanine 
nucleotide deletion in the putative NF-κB binding site of the SAA1 promoter. More 
recently four alleles have been identified for the SAA1A gene, only one of which 
(“allele 1”) has 3 guanine residues at the -97 to -99 position (Chen et al. 2012); the 
three other alleles have the single guanine nucleotide deletion. The allele frequency of 
“allele 1” in the Chen et al. (2012) study was 29.41%, thus for all other SAA1A-97delG 
alleles combined, the allele frequency was 70.59%. These SAA1A-97delG alleles are 
associated with reduced transcriptional activity of the SAA1 gene in vitro (Zhang et 
al. 2008b).  
Chen et al. (2012) found the expression pattern of the SAA genes differed 
depending on tissue type. SAA1A gene expression was found in the liver tissue of 
most cheetahs, however, no expression was found in the stomach or intestine. The 
SAA1B gene was not expressed in the liver, even in the presence of inflammation, 
suggesting the presence of a negative regulatory element in the SAA1B promoter 
upstream of the -667 position (Chen et al. 2012). In contrast, SAA3 gene expression 
was found in the liver and stomach, but not in the intestine (Chen et al. 2012). Both 
SAA1 and SAA3 gene expression is higher in the liver tissue of cheetahs with 
amyloidosis (Chen et al. 2012), suggesting that an increase in SAA protein production 
by the liver is important in the etiology of systemic amyloidosis.  
Humans also have four SAA protein genes (SAA1, SAA2, SAA3, and SAA4): 
the SAA1 and SAA2 genes are responsible for the increased production of SAA in 
the liver during the APR, whereas the SAA3 gene is a pseudogene and the SAA4 




Despite the upregulation of both SAA1 and SAA2 during the APR, it should also be 
noted that SAA1 is the protein primarily found in amyloid fibril deposits of human 
patients with secondary amyloidosis (Liepnieks et al. 1995). In humans, the addition 
of glucocorticoids enhances the induction of the SAA1 promoter by cytokines in a 
dose-dependent manner, however it does not enhance the induction of the SAA2 
promoter by cytokines at any concentration (Thorn and Whitehead 2002), which 
suggests elevated GCs may cause a predisposition to developing amyloid deposits. 
The observed enhancement of SAA1 expression by GCs is dependent on the 
cytoplasmic GR (Thorn and Whitehead 2002). It was determined this effect was the 
result of a GRE (glucocorticoid response element) that is uninterrupted in the SAA1 
promoter in humans, conferring glucocorticoid responsiveness of SAA under 
cytokine stimulation; the GRE in the promoter of the SAA2 gene is disrupted, 
resulting in the non-responsiveness to GCs (Thorn and Whitehead 2002). In the 
cheetah SAA1 gene promoter, the GRE is similarly disrupted, but the position of 
which is shifted and non-homologous to human, based on the sequence presented in 
Zhang et al. (2008b), thus it seems unlikely that glucocorticoids are directly 
increasing SAA1 transcription in cheetahs. 
In human populations, there is evidence that a SNP could explain population 
differences in secondary AA amyloidosis prevalence in rheumatoid arthritis patients: 
a thymine (T) nucleotide at the -13 position in the promoter region of the SAA1 gene 
is primarily associated with amyloidosis risk in these human populations (Moriguchi 
et al. 2001). Interestingly, cheetahs have a T at the -13 position in the SAA1 promoter 




2012), therefore all cheetahs may be at an increased risk of developing secondary AA 
amyloidosis.  
Structure of SAA and AA proteins in cheetah 
The SAA1 protein encoded by the SAA1 gene is the precursor to the amyloid 
A protein identified as the major component of amyloid fibrils deposited into tissues 
during systemic amyloidosis in cheetahs (Bergstrom et al. 2006, Johnson et al. 1997, 
Ofri et al. 1997). The cheetah SAA protein is 129 amino acid residues in length 
(Zhang et al. 2008b), compared to the 122 in the human SAA protein (Woo et al. 
1987). Initially it was reported that the cheetah AA protein had 90 amino acid 
residues (Johnson et al. 1997), however, more recently it has been reported to have 93 
amino acid residues (Zhang et al. 2008b); the shorter length of the AA protein 
compared to the SAA1 protein is due to the loss of an 18 amino acid N-terminal 
signal peptide (presumably for secretion from hepatocytes), and C-terminal amino 
acids from the SAA1 protein (Zhang et al. 2008b). The amyloid A protein isolated 
from cheetah liver tissue is predominantly 10kDa in size, but 8kDa size proteins have 
also been detected (Johnson et al. 1997). In comparison to human AA protein, 
cheetah AA protein is one amino acid residue shorter at the N terminus and contains 
an eight amino acid insertion between human residues 69-70 (Johnson et al. 1997). 
The molecular mass of AA protein in feces is approximately 7.0kDa, smaller than 
that found in the liver due to deletions from both N and C terminal regions (Zhang et 
al. 2008a). 
Amyloid fibrils isolated from liver tissue of cheetahs with amyloidosis only 




SAA1 and SAA3 genes in hepatocytes in cheetahs with amyloidosis. There is also 
evidence that undigested SAA protein is incorporated into amyloid fibrils in cheetah 
(Bergstrom et al. 2006).  
Amyloid A amyloidosis prevalence in cheetahs 
Systemic AA amyloidosis is an increasingly important cause of morbidity and 
mortality in captive cheetahs (Munson et al. 2005, Ofri et al. 1997, Papendick et al. 
1997). The number of cases of systemic amyloidosis in captive cheetahs has 
increased over time from 20% of individuals in pre-1990 necropsies to 70% of 
individuals in 1995 (Papendick et al. 1997). Amyloid deposition can be observed in 
many different tissues including the kidney, liver, adrenal gland, parathyroid gland, 
spleen, stomach, intestine, lymph node, heart, pancreas and esophagus (Chen et al. 
2012, Munson et al. 1999, Papendick et al. 1997). The majority of cases of AA 
amyloidosis can be considered "severe": 77% of cases involving the kidney and 71% 
of cases involving the liver (Papendick et al. 1997). Most commonly, amyloid 
deposition is observed in the kidneys, and among the cheetahs with renal amyloid, 
52% of individuals also have hepatic amyloid, thus systemic amyloidosis (Papendick 
et al. 1997). Hepatic amyloid has not been observed in cheetahs with an absence of 
renal amyloid (Papendick et al. 1997). Due to these factors, renal failure is the sole or 
partial cause of death in 74% of cheetahs with amyloidosis, compared to only 20% of 
cheetahs without amyloidosis (Papendick et al. 1997). There is no association 





Papendick et al. (1997) found that all cheetahs diagnosed with amyloidosis 
also suffered from other significant chronic inflammatory diseases in organs other 
than kidney, most commonly chronic lymphoblastic gastritis. In the Papendick et al. 
(1997) study, the prevalence of severe gastritis in captive cheetahs increased from 
16% of individuals in pre-1990 necropsies to 43% of individuals in 1995, an increase 
almost parallel to the increase in AA amyloidosis prevalence observed. Seventy-six 
percent of cheetahs with amyloidosis also had moderate to severe gastritis (Papendick 
et al. 1997), while close to 100% of cheetahs in captivity have some form of gastritis 
(Munson 1993, Munson et al. 1999, Munson et al. 2005). Both catecholamines and 
GCs induce a shift from TH1 (cellular immunity) to TH2 (humoral immunity) immune 
responses (Chrousos 2009, Dhabhar 2009, Elenkov and Chrousos 1999, Sapolski et 
al. 2000), therefore chronic stress-induced immune dysfunction might contribute to 
the persistence of Helicobacter infections in the stomach (generally defended against 
by the cellular immune response) (Chrousos 2009, Elenkov and Chrousos 1999), 
resulting in the high prevalence of gastritis in captive cheetahs compared to other 
species infected with the same stains of Helicobacter (Terio et al. 2011). Non-
inflammatory conditions associated with gastritis in captive cheetahs include 
multifocal perivascular interstitial cardiac fibrosis and adrenocortical hypertrophy 
(Munson et al. 1999, Munson et al. 2005, Papendick et al. 1997).  
Unrelated to stress or inflammation, there is some evidence presented that AA 
amyloidosis among captive cheetahs may be so highly prevalent because of 




cheetahs in a prion-like fashion (Caughey and Baron 2008, Zhang et al. 2008a) when 
housed as groups, however support of this hypothesis is limited. 
Amyloid A amyloidosis in other species 
In addition to cheetahs, AA amyloidosis has been identified in many other 
species. In some cases, susceptibility appears to be genetic (familial amyloidosis), 
such as observed in: Shar-Pei dogs (Rivas et al. 1993), Abyssinian (Boyce et al. 1984) 
and Siamese (van der Linde-Sipman et al. 1997) breeds of domestic cats, and black-
footed cats (Terio et al. 2008). Domestic cats are an interesting species to examine 
because the traditional domestic short hair (DSH) cat is not often affected by 
amyloidosis, while the Siamese and Abyssinian breeds have inherited forms of the 
disease, though the genetic factors implicated in the heritable disease are different 
between these two breeds. There are 10 amino acid positions of variability identified 
among DSH, Siamese and Abyssinian cats. The cheetah AA amino acid sequence is 
more similar to that of Abyssinian cats than DSH cats: there is homology at 5 
positions of variability with Abyssinian cats but only 2 with DSH cats (Johnson et al. 
1997). This suggests the possibility that cheetah AA protein may be structured in a 
way that makes it more amyloidogenic compared to the domestic cat AA protein. 
When isolating amyloid A protein from liver tissues, two unique amino acid 
substitutions are found in the Siamese cat AA sequence when compared to 
Abyssinian cats (Niewold et al. 1999, van der Linde-Sipman et al. 1997). The 52A-V 
substitution found in Siamese cats is common among many other animal species, 
however the 46Q-R substitution discovered is not found in other mammals, but has 




not homologous and thus could influence the AA protein structure (Niewold et al. 
1999). It is hypothesized that the AA sequence differences found among the breeds of 
domestic cats could explain the differences observed in the organ deposition patterns 
of amyloid during amyloidosis (Niewold et al. 1999).  
Among other species, AA amyloidosis is considered “reactive” and does not 
have a genetic basis, but rather appears secondary to other inflammatory conditions. 
Secondary amyloidosis has been noted in several species including (but not limited 
to): bighorn sheep (Hadlow and Jellison 1962), bat (Gruber and Linke 1996), Dorcas 
gazelle (Rideout et al. 1989) and humans (De Beer et al. 1982). In humans, 
persistently elevated SAA concentrations lead to increased amyloid load and organ 
deterioration (Gillmore et al. 2001); mortality, amyloid burden, and renal prognosis 
are all significantly correlated with serum SAA concentration (De Beer et al. 1982, 
Lachmann et al. 2007). Similar to cheetahs, the main manifestation of secondary 
amyloidosis is renal dysfunction and failure (Lachmann et al. 2007). However, 
despite the negative effects of elevated SAA concentrations due to persistent systemic 
inflammation, it has been shown that amyloid deposits can regress and organ function 
can recover if SAA concentrations are controlled (kept low) (Gillmore et al. 2001). A 
promising therapy using SAA-specific antisense oligonucleotides (ASO) has been 
shown to reduce SAA concentration in mice, particularly by facilitating a more rapid 
return to baseline after episodic bursts in SAA concentration (Kluve-Beckerman et al. 
2011).  SAA-specific ASOs were also shown to reduce amyloid deposition in treated 




Whether ASOs could be a therapy to treat systemic amyloidosis in either humans or 
cheetahs has yet to be investigated.  
Research objective and hypotheses 
The overall objective of the following studies was to identify the relationship 
between genetics, inflammation, and stress with serum concentrations of the SAA 
protein and the incidence of amyloid A amyloidosis in captive cheetah populations. 
The specific hypotheses investigated include: (1) the single nucleotide deletion 
(SAA1A-97delG) in the putative NF-κB binding site within the promoter region of the 
SAA1A gene locus is associated with lower serum SAA concentrations in cheetahs 
and with decreased prevalence of AA amyloidosis in deceased cheetahs; (2) higher 
fecal cortisol concentrations (as an indication of stress) are associated with higher 
serum SAA protein concentrations in cheetahs; (3) higher proinflammatory cytokine 
concentrations are associated with higher serum SAA protein concentrations in 
cheetahs; (4) elevated serum SAA concentrations are associated with greater amyloid 
deposition in the feces of cheetahs; and (5) the captive environment is associated with 
higher fecal cortisol concentrations, higher proinflammatory cytokine concentrations 
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Chapter 2: Linking genetic differences to amyloid A 
amyloidosis prevalence in the cheetah (Acinonyx jubatus) 
 
Abstract 
Systemic amyloid A (AA) amyloidosis is a major cause of morbidity and 
mortality among captive cheetahs in North America. The self-aggregating AA protein 
responsible for this disease is a byproduct of serum amyloid A (SAA) protein 
degradation, an acute phase protein highly upregulated during inflammation. 
Transcriptional induction of the cheetah SAA1 gene is dependent on both C/EBPβ 
and NF-κB cis-acting elements in the promoter region. Two alleles exist for a single 
nucleotide polymorphism (SNP) consisting of a single guanine nucleotide deletion in 
the putative NF-κB binding site of the SAA1 promoter. This study showed that the 
SAA1A-97delG allele was associated with decreased SAA protein concentrations in the 
serum of captive cheetahs, suggesting that genetic differences between the 
populations at this locus may be affecting AA amyloidosis prevalence. The allele 
frequency of the SNP, SAA1A-97delG, was significantly different between captive and 
wild cheetah populations: it was found more commonly among cheetahs in captivity. 
This disparity could be the result of past selection pressure in captivity favoring the 
SAA1A-97delG allele if the production of more SAA protein is linked to the 
development of AA amyloidosis; however, there was no significant difference in the 
frequency of the SAA1A-97delG allele between individuals who were confirmed AA 
amyloidosis positive and AA amyloidosis negative at the time of necropsy. Thus, 




in a decrease in the serum concentration of SAA protein in captive cheetahs, genotype 
is not associated with this disease within the North American population, suggesting 
that other factors are playing a role in the pathogenesis of AA amyloidosis among 
captive cheetahs. 
Introduction 
The acute phase response (APR) is a systemic reaction that occurs early 
during inflammation, initiated by cells of the innate immune system such as 
macrophages (Baumann and Gauldie 1994, Paltrinieri 2008). The liver is one of the 
primary targets for systemic inflammatory mediators such as the IL-1 type cytokines, 
IL-1β and TNF-α, as it is the primary location of acute phase protein (APP) 
production (Baumann and Gauldie 1994, Cerón et al. 2005, Jensen and Whitehead 
1998, Marhaug and Dowton 1994, Paltrinieri 2008). APPs, by definition, are proteins 
whose concentration in serum significantly increase or decrease during the APR and 
there is a high degree of similarity in the response patterns of several APPs to 
systemic inflammatory mediators during the APR across species (Baumann and 
Gauldie 1994, Cerón et al. 2005, Paltrinieri 2008).  
The major APPs that have been identified to date in the domestic cat are the 
serum amyloid A (SAA) protein and alpha-1-acid glycoprotein (AGP) (Cerón et al. 
2005, Kajikawa et al. 1999, Paltrinieri 2008). In humans, the concentration of SAA 
found in circulation bound to high-density lipoproteins increases as much as 1000-
fold within 24-48 hours of the initiation of inflammation (Marhaug and Dowton 
1994). The increase in SAA observed in domestic cats during the APR, 




other species, but still represents a major APP (Cerón et al. 2005, Giordano et al. 
2004, Kajikawa et al. 1999) and multiple studies have shown that SAA concentrations 
in sick cats are significantly higher than SAA concentrations in healthy cats 
(Giordano et al. 2004, Kajikawa et al. 1999, Kann et al 2012, Sasaki et al. 2003, 
Tamamoto et al. 2008).  
The SAA protein is well conserved throughout evolution, indicating an 
important biological function (Marhaug and Dowton 1994). Though its function is not 
completely understood, possible roles of SAA during the APR include the recruitment 
of inflammatory cells to the primary site of inflammation, involvement in lipid 
metabolism and transport, increasing cytokine production in monocytes/macrophages, 
stimulating nitric oxide production in macrophages, and scavenging for oxidized 
cholesterol, preventing prolonged tissue damage (Cerón et al. 2005, Jensen and 
Whitehead 1998, Paltrinieri 2008, Tamamoto et al. 2012). The SAA protein normally 
has a short half-life: approximately 90 minutes in normal serum (Marhaug and 
Dowton 1994), and the concentration of SAA in serum returns to normal following 
the termination of inflammation.  
In multiple species, including domestic cats, monocytes contribute to SAA 
degradation (Migita et al. 2001, Tamamoto et al. 2012); however, this process is 
inhibited in the presence of the cytokines IL-1β and IFN-γ (Migita et al. 2001) and 
glucocorticoids (Tamamoto et al. 2012). SAA itself can induce the expression and 
secretion of TNF-α and IL-1β from human macrophages through interactions with the 
TLR2 and TLR4 receptors (Niemi et al. 2011), thus contributing to its own 




of SAA mRNA during the APR due to the production of longer poly-A tails (Jensen 
and Whitehead 1998), contribute to the major increases in SAA concentration 
observed in serum during the APR. 
The N-terminal region of the SAA protein is the precursor for the amyloid A 
(AA) protein, the first 10-15 amino acid residues of which are amyloidogenic 
(Marhaug and Dowton 1994). In abundance, the AA protein polymerizes to form 
insoluble fibrils, which are deposited into the liver, kidney, spleen and other tissues 
(Marhaug and Dowton 1994). AA amyloidosis is a disease induced by the over-
accumulation and incomplete degradation of SAA, polymerization of AA protein into 
fibrils and subsequent tissue deposition, resulting in a disruption in organ 
functionality (Marhaug and Dowton 1994).  
It has been shown that SAA can also induce the secretion of cathepsin B from 
macrophages through direct activation of the P2X7 receptor (Niemi et al. 2011). This 
effect, considered together with evidence that cathepsin B is capable of degrading 
SAA into AA-like protein fragments (Rӧcken et al. 2005, Yamada et al. 1995), means 
chronic inflammation may lead to the extracellular proteolytic processing of SAA 
into AA amyloidogenic fragments. Thus, it is unsurprising that elevated SAA 
concentrations in serum have been found to correlate with AA amyloidosis and other 
inflammatory diseases in humans (Lachmann et al. 2007, Marhaug and Dowton 
1994).  
The CCAAT-enhancer-binding proteins (C/EBPs) are primarily responsible 
for the upregulation of SAA transcription during the APR (Ray and Ray 1994). The 




265bp region upstream of the transcription start site (Marhaug and Dowton 1994). 
Also located within this region, is a binding site for the transcription factor NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) (Marhaug and 
Dowton 1994). In the presence of stimulation from pro-inflammatory cytokines, such 
as TNF-α (Beg et al. 1993, Scheinman et al. 1995) and IL-1β (Barnes and Karin 
1997), the activated forms of C/EBPβ and NF-κB enter the nucleus and bind to the 
promoter region of target genes associated with inflammatory and immune responses, 
such as SAA (Barnes and Karin 1997, Beg et al. 1993, Ray and Ray 1994). IL-1β, 
TNF-α, and IL-6 proinflammatory cytokines have all been shown to stimulate hepatic 
SAA production during the APR (Baumann and Gauldie 1994, Cerón et al. 2005, 
Jensen and Whitehead 1998, Marhaug and Dowton 1994, Paltrinieri 2008). 
Four serum amyloid A protein genes (SAA1A, SAA1B, SAA3A, SAA3B) have 
been identified in the cheetah genome (Chen et al. 2012). Chen et al. (2012) found 
that both SAA1 and SAA3 gene expression is higher in the liver tissue of cheetahs 
with amyloidosis (Chen et al. 2012), suggesting that an increase in SAA protein 
production by the liver is important in the etiology of systemic amyloidosis. The 
SAA1 protein encoded by the SAA1 gene is the precursor to the AA protein 
identified as the major component of amyloid fibrils deposited into tissues during 
systemic amyloidosis in cheetahs (Bergstrom et al. 2006, Johnson et al. 1997, Ofri et 
al. 1997). The structure of the cheetah SAA1 genes show high similarity to the human 
SAA1 and mouse Saa1 genes (Zhang et al. 2008).  
Transcriptional induction of the SAA1 gene in cheetahs by IL-1β and IL-6 is 




Nucleotide sequences of NF-κB and C/EBPβ target sites are highly conserved 
between cheetah and human (Zhang et al. 2008), however Zhang et al. (2008) 
identified two alleles for a polymorphism consisting of a single guanine nucleotide 
deletion (SNP) in the putative NF-κB binding site of the SAA1A promoter. More 
recently, four alleles have been identified for the SAA1A gene, only one of which 
(“allele 1”) has 3 guanine residues at the -97 to -99 position (Chen et al. 2012); the 
three other alleles have the single guanine nucleotide deletion. These SAA1A-97delG 
alleles are associated with reduced transcriptional activity of the SAA1 gene in vitro 
(Zhang et al. 2008), though the effect in vivo has yet to be evaluated. 
Systemic amyloid A amyloidosis is an increasingly important cause of 
morbidity and mortality in captive cheetahs, affecting up to 70% of individuals at 
necropsy (Munson et al. 2005, Ofri et al. 1997, Papendick et al. 1997) and despite the 
high prevalence of AA amyloidosis observed in captive cheetahs in both North 
America and South Africa, wild cheetahs are virtually unaffected (Munson et al. 
2005).  The aim of this study was to determine if the SAA1A-97delG SNP in the putative 
NF-κB binding site of the SAA1A promoter is associated with the production of SAA 
protein in vivo and if so, if the difference in AA amyloidosis prevalence between the 




Banked fecal and serum samples were obtained from cheetahs housed at the 




Zoological Park (NZP) in Washington, DC (fecals: n=38 cheetahs from multiple 
institutions, serum: n=20 cheetahs at NZP-SCBI only). Previously extracted DNA or 
white blood cell samples and banked serum samples were obtained from the Cheetah 
Conservation Fund (CCF) in Namibia from wild-born cheetahs (DNA or WBC: n=47 
cheetahs, serum: n=34 cheetahs). Fresh and formalin fixed tissue samples from 
deceased cheetahs with known AA amyloidosis histology were provided upon request 
by the cheetah Species Survival Plan® pathologist (n=48 cheetahs).  
DNA isolation 
DNA was extracted from fecal samples using the QIAamp® DNA Stool Mini 
Kit (QIAGEN®) following the protocol for the isolation of DNA from stool for 
human DNA analysis. DNA was extracted from white blood cell samples using the 
QIAamp® DNA Blood Mini Kit (QIAGEN®) following the protocol for DNA 
purification from blood or body fluids (spin protocol). DNA was extracted from fresh 
and formalin fixed tissues using the PUREGENE® Genomic DNA Purification Kit 
(Gentra Systems) following the solid tissue protocol with an extended incubation time 
in the Cell Lysis Buffer provided.  
Amplification and genotyping of the NF-κB binding site in the SAA1A promoter 
region 
The putative NF-κB binding site within the SAA1A promoter region was 
amplified using a semi-nested polymerase chain reaction (PCR). Initially, a larger 
region of the promoter was amplified using the F3A forward primer specific to the 




promoter sequence reported in Zhang et al. (2008) and named “SAA1R”                       
(5’-ACTGTGCCCTCCCCGTTGGG-3’). The second round of PCR used the SAA1F 
forward primer (5’-GACCGGCCAAGCTGGCTTCC-3’) with the SAA1R reverse 
primer to produce a smaller PCR product for sequencing containing the putative    
NF-κB binding site (Figure 2.1). The first PCR product was either purified using the 
QIAquick® Gel Extraction Kit (QIAGEN®) or was treated with ExoSAP-IT® 
(Affymetrix) before being used as template for the second reaction. Both polymerase 
chain reactions were carried out using GoTaq® Green Master Mix (Promega) and 
entailed an initial denaturing step of 94⁰C for 3 mins, followed by 35 cycles of 94⁰C 
for 30sec (denature), 60⁰C for 30sec (annealing) and 72⁰C for 30sec (extension), 
followed by a final extension step of 72⁰C for 10min. PCR products were genotyped 
by either standard Sanger sequencing via GENEWIZ® or by microsatellite analysis 
through the use of a fluorescently labelled SAA1F primer (SAA1F-FAM). To prepare 
samples for sequencing, the PCR products were purified using the QIAquick® Gel 
Extraction Kit (QIAGEN®) and premixed with primer before shipping to 
GENEWIZ®. Chromatograms were interpreted for determination of genotype. 
SAA1A+/+ and SAA1A-97delG/-97delG genotypes contained clear distinguishable peaks on 
the chromatogram. SAA1A+/-97delG heterozygotes generated a chromatogram with 
overlapping peaks beginning at the -97 guanine deletion site in the SAA1A promoter 
(Figure 2.2). When running the fluorescently labelled PCR products on the ABI 
PRISM® 310 Genetic Analyzer, homozygotes produced a single peak, and 
heterozygotes produced two peaks. Homozygote genotypes could be distinguished 











Figure 2.2. Representative chromatograms for the three SAA1A promoter genotypes after Sanger sequencing. 






Figure 2.3. Representative output for the three SAA1A promoter genotypes from the 
ABI PRISM® 310 Genetic Analyzer. Top: homozygous SAA1A-97delG; Middle: 





To confirm specific amplification of the SAA1A gene only, second round 
PCR primers (SAA1F/R; non-specific: amplifies both SAA1A and SAA1B 
promoters) were used to amplify the SAA1 promoter region for six cheetahs (2 with 
each genotype) and compared to the nested PCR results. The SAA1B gene lacks the 
SAA1A-97delG SNP (Chen et al. 2012), thus amplification of both SAA1A and SAA1B 
promoters simultaneously should produce 4 amplified products: 2 should always be 
SAA1A+ and the other 2 will be dictated based on SAA1A genotype.  See Appendix I 
for representative results.  
Quantification of serum amyloid A protein concentration in serum 
Serum amyloid A concentration was measured in serum samples using the 
PhaseTM Range Multispecies SAA ELISA kit (Tridelta Development Ltd: Cat No. TP 
802). Serum samples were diluted 1:100 in the provided sample diluent before use. 
Anti-SAA/HRP conjugate (50µl) and sample/control/standard (50µl, in duplicate) 
were added to each pre-coated well and incubated for 1.5 hours on a shaker at room 
temperature. After washing, 100µl of TMB substrate solution was added to each well, 
and the plate was incubated for 15 minutes at room temperature. Stop solution was 
added (100µl) and absorbance for each well was read at 450nm using 620nm as a 
reference. 
Statistical analysis 
Serum amyloid A concentration was log (base 10) transformed before data 
analysis due to a significant departure from normality. Log10[SAA] was compared 




of SNP copies (of the SAA1A-97delG SNP) as a quantitative factor and captive 
population (NZP-SCBI vs. CCF) as a fixed categorical factor, assuming 
heterogeneous variances for captive populations, using PROC MIXED in SAS 
Enterprise Guide version 6.1 with the Kenward and Roger (DDFM=KR) option for 
adjustment of denominator degrees of freedom. Initially, the interaction term between 
SNP copies and captive population was included in the statistical model, however, it 
was removed due to being highly insignificant. 
 Allele frequencies for the captive North American and wild Namibian cheetah 
populations were estimated using the software MENDEL (Lange et al. 2013) utilizing 
known genotypes and complete pedigree information available for all individuals. 
Genotype and allele frequencies were compared between populations using a Chi-
square Test of Homogeneity. 
Results 
Serum amyloid A concentration in captive cheetahs is associated with genotype 
Based on the ANCOVA, a significant decrease in the log10SAA concentration 
in serum was found as the number of copies of the SAA1A-97delG SNP increased 
(P=0.0453; Figure 2.4). There was also a significant effect of captive population: 
captive cheetahs at NZP-SCBI have significantly higher log10SAA concentrations in 
serum compared to captive cheetahs at CCF (P=0.0003; Figure 2.4), regardless of the 
number of SNP copies. Interestingly, even captive cheetahs at NZP-SCBI who were 
homozygous for the SAA1A-97delG allele had higher log10SAA concentrations, on 
average, than CCF cheetahs who were homozygous SAA1A+ (Figure 2.4). The 







Figure 2.4. Serum concentrations of serum amyloid A (SAA) protein in captive 
cheetahs at NZP-SCBI and CCF. Unrestricted least-square means of the log (base 10) 






four times the amount of variation in log10SAA concentrations as was explained by 
genotype. 
Differences in SAA1A-97delG allele frequencies between populations 
When examining the genotype frequencies of the SNP in the NF-κB binding 
site in the SAA1A promoter region of the captive North American and wild Namibian 
cheetah populations, there was no evidence to reject Hardy-Weinberg equilibrium in 
either population, thus allele frequencies between populations were compared. The 
allele frequency of the single base pair deletion in the promoter region of the SAA1A 
gene, SAA1A-97delG, was significantly different between populations (P=0.0414): the 
SAA1A-97delG allele is more common in the captive North American cheetah 
population when compared to wild Namibian cheetahs (Table 2.1).  
 Allele frequencies were also compared among deceased cheetahs from the 
captive North American population between individuals who were confirmed to be 
AA amyloidosis positive and those confirmed AA amyloidosis negative at the time of 
necropsy. There was no significant difference in the frequency of the SAA1A-97delG 
allele between these two groups of captive cheetahs (Table 2.2). A power analysis 
was performed using PROC POWER in SAS Enterprise Guide version 6.1 to 
determine the number of cheetahs that would need to be genotyped to declare the 
difference in allele frequencies observed significantly different and it was concluded 
that 52 cheetahs per group (positive/negative) would be required to ensure 90% 
power. Additional voucher samples may be genotyped in the future to increase the 
power of the analysis, but based on the current available data, AA amyloidosis 

















Population Allele Estimated1 Frequency 
± Standard Error 
Namibia  SAA1A-97delG   0.5032a ±0.0600 
(Wild, n=47) SAA1A+ 0.4968  ±0.0600 
North America SAA1A-97delG   0.7158b ±0.0796 
(Captive, n=38) SAA1A+ 0.2842  ±0.0796 
 
Table 2.1. Estimated allele frequencies of the SAA1A-97delG SNP for wild cheetahs in 
Namibia and captive cheetahs in North America. a,b Indicates a significant difference 
in allele frequency based on the Chi-square Test of Homogeneity, P=0.0414. 
1Estimated using the software MENDEL (Lange et al. 2013) utilizing complete 























Allele Estimated1 Frequency 
± Standard Error 
Positive SAA1A-97delG   0.8750 ±0.1170 
(n=27) SAA1A+ 0.1250 ±0.1170 
Negative SAA1A-97delG   0.5980 ±0.0781 
(n=21) SAA1A+ 0.4020 ±0.0781 
 
Table 2.2. Estimated allele frequencies of the SAA1A-97delG SNP for captive cheetahs 
confirmed positive or negative for AA amyloidosis at time of necropsy. 1Estimated 
using the software MENDEL (Lange et al. 2013)) utilizing complete pedigree 







Amyloid A amyloidosis has been identified in many species. In some cases, 
susceptibility appears to be genetic (familial amyloidosis), as observed in: Shar-Pei 
dogs (Rivas et al. 1993), Abyssinian (Boyce et al. 1984) and Siamese (van der Linde-
Sipman et al. 1997) breeds of domestic cats, and black-footed cats (Terio et al. 2008). 
Among other species, AA amyloidosis is considered “reactive” and does not have a 
genetic basis, but rather appears secondary to other inflammatory conditions, as 
observed in: bighorn sheep (Hadlow and Jellison 1962), bat (Gruber and Linke 1996), 
Dorcas gazelle (Rideout et al. 1989) and humans (De Beer et al. 1982). Domestic cats 
are an interesting species to examine because the traditional domestic short hair 
(DSH) cat is not often affected by amyloidosis, while the Siamese and Abyssinian 
breeds have inherited forms of the disease, though the genetic differences implicated 
in the heritable disease are different between these two breeds. The cheetah AA 
protein amino acid sequence is more similar to that of Abyssinian cats than DSH cats 
(Johnson et al. 1997), which suggests the possibility that cheetah AA protein may be 
structured in a way that makes it more amyloidogenic compared to the domestic cat 
AA protein. However, AA amyloidosis is uncommon among wild cheetahs (Munson 
et al. 2005), suggesting that the AA protein structure is not the cause of AA 
amyloidosis observed in cheetahs, therefore not of a true “familial” type. 
The identification of the SNP in the promoter region of the SAA1A gene in 
cheetahs by Zhang et al. (2008), suggested that AA amyloidosis in captive cheetahs 
may still be linked to genetic differences, as the SAA1A-97delG SNP is associated with a 




shows that the SAA1A-97delG SNP is similarly associated with a decrease in the SAA 
concentration in serum of captive cheetahs. However, more striking were the 
differences in SAA concentrations that were observed between the two captive 
populations examined, NZP-SCBI and CCF. NZP-SCBI cheetahs had significantly 
higher SAA concentrations compared to CCF cheetahs. Though both populations are 
captive, it seems that major environmental differences between the captive 
environments at NZP-SCBI and CCF play a bigger role in the differences in SAA 
concentrations observed. This supports previous theories that suggests the high 
prevalence of AA amyloidosis observed among captive cheetahs is the result of 
differences imposed by the captive environment.  
It has been widely accepted that captivity imposes psychological stress on 
several species of animals (e.g. camels (Padalino et al. 2014), house sparrows (Martin 
et al. 2012), orangutans (Weingrill et al. 2011), chukar partridge (Dickens et al. 
2009), and Bengal tigers (Sajjad et al 2011)). Psychological stress activates the 
hypothalamic-pituitary-adrenal (HPA) axis leading to the production and release of 
glucocorticoids (GCs), such as cortisol and corticosterone (Chrousos 1995). There is 
a positive, synergistic effect of GCs with cytokines in the induction of SAA synthesis 
during the APR (Chrousos 1995, Marhaug and Dowton 1994). This effect is the result 
of the upregulation of cytokine receptors on the surface of hepatic cells by GCs 
(Baumann and Gauldie 1994, Wiegers and Reul 1998), increasing the sensitivity of 
the hepatic cells to cytokine stimulation (Baumann and Gauldie 1994, Paltrinieri 
2008, Thorn and Whitehead 2002, Wiegers and Reul 1998). During the APR, IL-1β 




inducing the production of cortisol (Baumann and Gauldie 1994). Therefore, it 
appears GCs play a role in the systemic inflammatory response by increasing 
production of APPs during the APR. There is both functional (hypercortisolemia) and 
morphological (adrenal hyperplasia) evidence for chronic stress (persistently elevated 
glucocorticoids) among captive cheetahs, at levels much greater than their wild 
counterparts (Terio et al. 2004). Therefore, it is possible that chronic stress among 
captive cheetahs, imposed by the environment, potentiates the development of AA 
amyloidosis during inflammation, resulting in the observed increase in the incidence 
of AA amyloidosis among captive cheetahs compared to animals in the wild (Munson 
et al. 2005). 
Papendick et al. (1997) found that all cheetahs diagnosed with amyloidosis 
also suffered from other significant chronic inflammatory diseases in organs other 
than kidney, most commonly chronic lymphoblastic gastritis. The prevalence of 
severe gastritis in captive cheetahs increased from 16% of individuals in pre-1990 
necropsies to 43% of individuals in 1995, an increase almost parallel to the increase 
in AA amyloidosis prevalence observed in the same study (Papendick et al. 1997). 
Seventy-six percent of cheetahs with amyloidosis have moderate to severe gastritis 
(Papendick et al. 1997), while close to 100% of captive cheetahs have some form of 
gastritis (Munson 1993, Munson et al. 1999, Munson et al. 1995). Therefore, the high 
prevalence of AA amyloidosis in captive cheetahs is more likely a result of chronic 
inflammation inducing the overproduction of SAA in general, particularly in animals 




In human populations, there is evidence that a SNP could explain population 
differences in secondary AA amyloidosis prevalence in rheumatoid arthritis patients: 
a thymine (T) nucleotide at the -13 position in the promoter region of the SAA1 gene 
is primarily associated with amyloidosis risk in these human populations (Moriguchi 
et al. 2001). Interestingly, cheetahs have a T at the -13 position in the SAA1 promoter 
(Zhang et al. 2008) and this nucleotide position is not polymorphic (Chen et al. 2012), 
therefore all cheetahs may be at an increased risk of developing secondary AA 
amyloidosis.  
It has been shown that persistently elevated SAA concentration leads to 
increased amyloid load and organ deterioration in humans (Gillmore et al. 2001): 
mortality, amyloid burden, and renal prognosis are all significantly correlated with 
serum SAA concentration (De Beer et al. 1982, Lachmann et al. 2007). Similar to 
cheetahs, the main manifestation of secondary amyloidosis in human patients is renal 
dysfunction and failure (Lachmann et al. 2007). 
This study has also showed that the SAA1A-97delG allele is significantly more 
common among the captive North American population compared to the wild 
Namibian cheetah population. It is possible that captivity-induced chronic stress 
and/or inflammation has imposed natural selection pressure within the captive 
population to favor the SAA1A-97delG allele (associated with less SAA production). 
However, the lack of a relationship between the SNP and AA amyloidosis diagnosis 
found in this study and the Chen et al. (2012) study suggests that the population 




founder population or genetic drift within the captive North American, as opposed to 
selection. 
Conclusion 
This study was the first to demonstrate that the concentration of SAA protein 
in serum in captive cheetahs is associated with the SAA1A-97delG SNP in the promoter 
region of the SAA1A gene. However, based on the significant difference observed 
between captive populations and the lack of association between the SNP and AA 
amyloidosis diagnosis in captive North American cheetahs, the high prevalence of 
AA amyloidosis observed among captive cheetahs is not primarily attributable to 
genetic differences at this locus, but rather appears to be related to stress and/or 
chronic inflammation within captivity. 
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Chapter 3: Induction of cytokine production in cheetah 
(Acinonyx jubatus) peripheral blood mononuclear cells by LPS 




Peripheral blood mononuclear cells were isolated from the whole blood of 
cheetahs and stimulated with lipopolysaccharide (LPS) to establish cross-reactivity 
between cheetah proinflammatory cytokines TNF-α, IL-1β, and IL-6 and feline-
specific cytokine antibodies provided in commercially available ELISA kits (R&D 
Systems). To enable the use of these kits (designed for cell culture supernatants) for 
analyzing cytokine concentrations in cheetah serum, percent recovery and parallelism 
of feline cytokine standards in serum were also evaluated. This study validates the use 
of commercially available feline DuoSet® ELISA kits (R&D Systems) for measuring 
the concentration of proinflammatory cytokines TNF-α, IL-1β, and IL-6 in serum 
samples collected from cheetahs based on positive cross-reactivity of cheetah proteins 
with feline-specific antibodies, percent recovery and parallelism. 
Introduction 
Proinflammatory cytokines are produced and released from lymphocytes in 
response to external stimuli that signal the presence of foreign pathogens or tissue 
damage. Lipopolysaccharide (LPS), an endotoxin found on the surface of gram-
negative bacteria, binds to the Toll-like receptor 4 (TLR4) on lymphocytes eliciting a 




inducing the production of proinflammatory cytokines from lymphocytes in cell 
culture. A dose of 5µg/ml of LPS has been shown to be sufficient to increase TNF-α 
production in feline peritoneal exudate cells in culture (Otto and Rawlings 1995). 
When injected into domestic cats and dogs, LPS stimulates an increase in rectal 
temperature (DeClue et al. 2009, LeMay et al. 1990), as well as increases in plasma 
concentrations of TNF-α and IL-6 (DeClue et al. 2009, LeMay et al. 1990, Otto and 
Rawlings 1995). In both domestic cats and dogs, IL-6 activity persists longer than 
TNF activity after LPS injection (DeClue et al. 2009, LeMay et al. 1990). In domestic 
cats, there is a delayed response of plasma IL-1β concentrations to LPS stimulation 
(compared to TNF-α and IL-6): a small increase in IL-1β is observed 6hr post-LPS 
stimulation (DeClue et al. 2009). IL-1β responses in dogs are unknown. 
 The goal of this study was to produce cheetah proinflammatory cytokines in 
vitro through the isolation and stimulation of peripheral blood mononuclear cells 
(PBMCs) isolated from whole blood using LPS to establish cross-reactivity between 
cheetah cytokines and feline-specific cytokine antibodies provided in commercially 
available ELISA kits (R&D Systems). To enable the use of these kits (designed for 
cell culture supernatants) for analyzing cytokine concentrations in cheetah serum, 




Fresh whole blood samples (n=3 cheetahs) were collected in Vacutainer® 




Biology Institute (SCBI) in Front Royal, VA. Whole blood samples were transported 
on ice to the University of Maryland for PBMC isolation and cell culture. Samples 
were diluted 1:2 with PBS and slowly layered on lymphocyte separation medium 
(10ml) and centrifuged for 30 min at 400 × g. Cells at the interface of the media were 
collected, washed in PBS, and resuspended in 11ml cell culture media (RPMI-1640 
media, pH 7.4 supplemented with 10% fetal bovine serum, 2mM glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin). Final concentration of cells was approximately 10 
million cells/ml media for each sample.  
Stimulation of cheetah PBMCs with LPS 
Isolated lymphocytes were added to a 24-well plate in 1.5ml of media, either 
undiluted or as a 5x, 25x, 50x or 100x dilution in cell culture media (Figure 3.1; 3 
replicates, 1 plate per cheetah). Plates were incubated for 2 hours at 5% CO2 at 37ºC 
to allow monocytes to adhere to the plate. Wells were gently washed with media via 
careful aspiration to remove any unbound lymphocytes. Media was replaced (1.5ml) 
either with or without 5µg/ml LPS (Figure 3.1). Cell culture supernatants were 
removed at 24, 48 or 72 hours post-LPS stimulation (Figure 3.1) and stored at -20ºC 
until assayed. 
Quantification of cytokine production in cell culture supernatants 
Feline DuoSet® ELISA kits (R&D Systems) for TNF-α, IL-1β, and IL-6 were 
used following the manufacturer’s instructions to quantify the concentration of 















Parallelism and cytokine recovery in serum 
Feline DuoSet® ELISA kits (R&D Systems) for TNF-α, IL-1β, and IL-6 were 
used following the manufacturer’s instructions (substituting 10% FBS in PBS for the 
blocking buffer) to quantify the concentration of cytokines in different dilutions of 
cheetah serum (undiluted serum, 2x, 3x, 4x, 5x, 10x, 20x, 50x) spiked with a constant 
quantity of standard towards the lower end of the range of detection (25pg/ml for 
TNF-α, 50pg/ml for IL-1β and IL-6) to investigate if the dilution of serum affected 
the percent recovery of the standard.  
 Feline DuoSet® ELISA kits (R&D Systems) for TNF-α, IL-1β, and IL-6 were 
used following the manufacturer’s instructions (substituting 10% FBS in PBS for the 
blocking buffer) to quantify the concentration of cytokines in a constant dilution of 
cheetah serum (1:2) spiked with multiple concentrations of standard (0, 10, 25, 50, 
100, 356.25, 712.5, and 1425 pg/ml TNF-α and 0, 20, 50, 100, 200, 787.5, 1575, 3150 
pg/ml IL-1β and IL-6) to check for parallelism between the spiked samples and the 
standard curve. 
Statistical analysis 
To investigate differences in cytokine production by PMBCs in cell culture, a 
repeated-measures ANOVA in PROC MIXED of SAS Enterprise Guide (version 6.1) 
was conducted with dilution factor, LPS stimulation (Yes or No), time and all 
associated interaction terms as fixed effects and cheetah as a random effect (block), 
with time as the repeated variable using an unstructured covariance matrix. A one-




stimulation (at undiluted and 5x concentrations of cells only) due to the incomplete 
factorial treatment structure. The effects of dilution factor and time were examined 
for LPS stimulated cell culture supernatants only. Treatment least square means were 
compared using a Bonferroni correction to control for an experimentwise error rate at 
α=0.05. 
Results 
LPS stimulation of cheetah PBMCs produces a measurable, cell concentration 
dependent increase in production of TNF-α, IL-1β, and IL-6 
There was a significant positive induction of proinflammatory cytokine 
production by cheetah PBMCs in culture following stimulation with LPS for all three 
cytokines measured compared to unstimulated cells (Figure 3.2): TNF-α (P=0.0007), 
IL1-β (P<0.0001), and IL-6 (P=0.0196). The amount of cytokines produced was also 
dependent on the concentration of PBMCs present (Table 3.1). A statistically 
significant effect of time was only observed in supernatants from undiluted cells. The 
concentrations of TNF-α and IL-1β both decreased over time, though the 
concentration of TNF-α appeared to decrease more rapidly (Figure 3.2, Table 3.1). 
There was no significant difference observed in IL-6 concentration across time points 
(Figure 3.2, Table 3.1). 
Percent recovery of cytokine standard from cheetah serum is dependent on the 
dilution factor 
The dilution of serum used when spiking samples with a constant, known 




Figure 3.2. Cytokine concentrations in cell culture supernatants from cheetah PBMCs 
(undiluted and 5X) at 24, 48 and 72 hours post-LPS stimulation. (A) TNF-α; (B) IL-














  Cytokine Concentration 
LSmeans ± SE (pg/ml) 
 Dilution 
Factor 
24hrs 48hrs 72hrs 
TNF-α Undiluted 
A723.09 ± 220.39 a B338.69 ± 96.44 a C161.24 ± 39.68 a 
 5x 235.06 ± 90.39
 ab 154.24 ± 55.20 ab 91.06 ± 3.97 ab 
 25x 71.47 ± 14.15
 b 49.59 ± 8.91 b 40.16 ± 2.64 b 
 50x 38.13 ± 4.89
 b 33.52 ± 2.76 b 30.16 ± 1.97 b 
 100x 27.09 ± 2.21
 b 27.12 ± 2.84 b 27.36 ± 0.51 b 
 Media *** *** 18.47 ± 1.60
 b 
IL-1β Undiluted 
A1091.86 ± 209.14 a AB943.11 ± 190.54 a B747.42 ± 95.56 a 
 5x 486.70 ± 116.09
 b 530.05 ± 125.80 ab 387.18 ± 33.70 b 
 25x 244.48 ± 38.81
 b 225.31 ± 41.41 b 173.74 ± 28.02 bc 
 50x 117.74 ± 8.84
 b 132.93 ± 5.99 b 102.53 ± 23.64 c 
 100x 77.49 ± 11.04
 b 84.56 ± 13.04 b 79.11 ± 17.32 c 
 Media *** *** *** 
IL-6 Undiluted 
A229.59 ± 84.29 a A251.93 ± 96.33 a A235.36 ± 53.64 a 
 5x 84.41 ± 15.64 a 87.22 ± 20.74 a 75.32 ± 6.19 b 
 25x *** *** *** 
 50x *** *** *** 
 100x *** *** *** 
 Media *** *** *** 
Table 3.1. Cytokine concentrations in cell culture supernatants from cheetah PBMCs 
24, 48 and 72 hours post-LPS stimulation. A,B,CDesignate significant differences 
within the undiluted cell culture supernatants across time. a,b,cDesignate significant 
differences across dilution factors at the given time point. Mean comparisons were 
declared significant at where P<0.05 after Bonferroni correction. ***indicates 






measured (TNF-α, IL-1β, and IL-6; Figure 3.3). In all cases, percent recovery 
increased as the serum sample dilution increased (Figure 3.3). There was a large 
amount of variation between the three cytokine assays in percent recovery at a given 
dilution factor. A 1:2 dilution of serum resulted in approximately 45%, 82%, and 7% 
recovery of TNF-α, IL-1β, and IL-6 standards, respectively (Figure 3.3).   
Parallelism observed between standards and spiked serum samples 
Adequate parallelism between spiked serum (1:2 dilution) samples and the 
standard curve was observed across a large range of cytokine concentrations for all 
three cytokines measured (TNF-α: 31.25-1000 pg/ml, r=0.99690, P<0.0001; IL-1β: 
31.25-2000 pg/ml, r=0.99634, P<0.0001; and IL-6: 62.5-2000pg/ml, r=0.99635, 
P<0.0001). Larger departures from parallelism as the concentration of the spike 
increased was observed (Figure 3.4).  
Discussion 
The ability to measure inflammatory markers, such as serum concentrations of 
cheetah proinflammatory cytokines, has become progressively more desirable due to 
the high prevalence of several diseases observed within captive cheetah populations 
in North America and South Africa (Munson et al. 2005). A disease that has become 
of increasing concern is systemic amyloid A (AA) amyloidosis (Munson et al. 2005, 
Ofri et al. 1997, Papendick et al. 1997), which has been shown to be associated with 
other chronic inflammatory diseases, most commonly chronic lymphoblastic gastritis 
(Papendick et al. 1997). Close to 100% of cheetahs in captivity have some form of 
















Figure 3.3. Effect of increasing serum dilution on percent recovery of cytokine 










Figure 3.4. Parallelism between cytokine standards and cheetah serum (1:2 dilution) 





chronic or persistent episodes of inflammation. Chronic systemic inflammation leads 
to the persistent upregulation of production of the amyloid A precursor protein, serum 
amyloid A (SAA), as well as a decrease in SAA degradation and an accumulation of 
SAA protein in the serum, providing evidence that it plays a role in AA amyloidosis 
pathogenesis.  
The systemic inflammatory mediators generally responsible for the 
upregulation of SAA production are the IL-1 type cytokines, such as IL-1β and TNF-
α (Baumann and Gauldie 1994, Jensen and Whitehead 1998, Marhaug and Dowton 
1994, Paltrinieri 2008). The actions of the IL-1 type cytokines on the production of 
acute phase proteins, such as SAA, are also often synergistically enhanced in the 
presence of IL-6 (Baumann and Gauldie 1994, Cerón et al. 2005, Jensen and 
Whitehead 1998). Therefore, there is a need to be able to measure TNF-α, IL-1β, and 
IL-6 in cheetah serum samples to investigate how proinflammatory cytokines may be 
related to the diseases observed in captive cheetahs, such as AA amyloidosis. 
Previous work has shown the amino acid sequence of the cheetah IFN-γ 
cytokine to be 99% homologous to the domestic cat sequence (Maas et al. 2010), thus 
it would be expected that there is conservation across most protein binding sites. 
Cheetah proinflammatory cytokines TNF-α, IL-1β, and IL-6 have not been 
sequenced, but it was expected that there may be similarly high levels of homology 
between the cheetah and domestic cat proteins such that ELISA kits designed to bind 
to domestic cat proteins would cross-react with cheetah proteins. This study has 
shown that the feline-specific antibodies provided in the commercially available 




Systems) are cross-reactive with cheetah proinflammatory cytokines as they were 
able to detect increases in cytokine concentrations in PMBC cell culture supernatants 
post-LPS stimulation (vs. control) as well as show cell concentration dependent 
responses.  
There was substantial variability in the ability of the ELISA kits to detect 
TNF-α, IL-1β, and IL-6 in serum samples. The IL-1β ELISA worked quite well with 
cheetah serum, even at lower dilution factors. The TNF-α ELISA worked fairly well 
with cheetah serum, though the percent recovery was less than ideal. The percent 
recovery was very poor for the IL-6 ELISA. Therefore, even though parallelism was 
acceptable for all ELISA kits, it is likely that TNF-α and most certainly IL-6 
concentrations will be underestimated when measuring cheetah serum samples. 
Percent recovery was improved by increasing the dilution factor. However, assuming 
that physiological concentrations of these cytokines in serum is going to be fairly low 
in healthy individuals, it is not possible to use a very high dilution factor. A previous 
study in domestic cats used a 1:2 dilution of plasma demonstrating a peak in IL-6 at 
1200pg/ml, and IL-1β concentrations were measured around 86pg/ml following a 
low-dose endotoxin infusion (DeClue et al. 2009). The limit of detection for the IL-6 
assay on cheetah serum was 62.5pg/ml. Therefore, if peaks in the concentrations of 
IL-6 in cheetah serum are in the same range as domestic cats, increasing the dilution 
factor up to a 1:10 may be possible to help improve percent recovery and parallelism, 





This study has validated the use of commercially available ELISA kits (R&D 
Systems) for measuring the concentration of proinflammatory cytokines TNF-α, IL-
1β, and possibly IL-6 in serum samples collected from cheetahs based on positive 
cross-reactivity of cheetah proteins with feline-specific antibodies, percent recovery 
and parallelism. 
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Chapter 4: Evaluation of the effects of chronic stress and 
inflammation on serum amyloid A concentrations in serum 
associated with increasing AA amyloidosis prevalence in 
captive cheetah populations 
 
Summary 
Systemic amyloid A (AA) amyloidosis is a major cause of morbidity and 
mortality among captive cheetahs in North America, however wild cheetahs are 
virtually unaffected. The AA protein, a self-aggregating protein responsible for this 
disease, is a byproduct from the degradation of serum amyloid A (SAA) protein, an 
acute phase protein highly upregulated during inflammation. IL-1β, TNF-α, and IL-6 
proinflammatory cytokines have all been shown to stimulate hepatic SAA production 
during the acute phase response (APR). There is a positive, synergistic effect of 
glucocorticoids with cytokines in the induction of SAA synthesis during the APR. 
The aim of this study was to investigate the potential effect of stress and 
inflammation on SAA production in order to gain a better understanding of the 
differences observed in AA amyloidosis prevalence between captive and wild 
populations.  
A multivariate statistical approach (canonical discriminant analysis) was taken 
to investigate how population differences across multiple correlated variables 
measured can distinguish the populations from each other. Two significant canonical 
discriminant functions, Can1 and Can2, were produced that defined the differences 




cheetahs). Can1 best defined the difference between NZP-SCBI cheetahs and 
Namibian cheetahs (CCF and wild), and Can2 best defined the separation between 
Namibian cheetahs, CCF vs. wild.  
Log10SAA concentration was significantly positively correlated with Can1 
(r=0.54, P<0.0001), which had similar significant positive correlations with baseline 
cortisol, average cortisol, and baseline standard deviation, and was negatively 
correlated with IL-1β and TNF-α. The low cytokine concentrations found among 
NZP-SCBI cheetahs compared to CCF and wild cheetahs is possibly the result of 
proinflammatory cytokine production getting suppressed in immune cells via 
glucocorticoids. Log10SAA concentration was not associated with Can2, as 
log10[SAA] was not significantly different between CCF and wild cheetah 
populations. Can2 was positively correlated with baseline cortisol, average cortisol, 
baseline standard deviation, total standard deviation, as well as IL-1β and TNF-α 
concentrations.  
Closer examination of the effects of environmental factors including exercise, 
enclosure size and exposure to humans on serum SAA protein concentrations within 
the CCF population revealed that cheetahs in smaller enclosures (<10 acres) had 
significantly higher log10[SAA] than cheetahs kept in larger enclosures (P=0.0190). 
Similarly, baseline cortisol and average cortisol were marginally higher in cheetahs 
kept in smaller enclosures (P=0.0793 and P=0.0534, respectively). In humans, 
elevated SAA concentrations have been found to correlate with AA amyloidosis 
incidence. Thus, it appears the best strategy for decreasing AA amyloidosis 




stress, which could help re-establish proper immune system homeostasis and mitigate 
the overproduction of SAA protein.  
Introduction 
Stress can be defined as a physiological or psychological state in which 
homeostasis is, or perceived to be, threatened (Chrousos 2009, Dhabhar 2009, 
Elenkov and Chrousos 1999). Stress activates the sympathetic nervous system which 
stimulates the release of catecholamines (epinephrine and norepinephrine; E and NE) 
from the adrenal medulla. Stress also results in activation of the hypothalamic-
pituitary-adrenal (HPA) axis, signaling the release of adrenocorticotropic hormone 
(ACTH) from the anterior pituitary into circulation. The ACTH signal is received by 
cells of the adrenal cortex, stimulating the production and release of glucocorticoids 
(GCs), such as cortisol and corticosterone. In short, acute stress is characterized by 
the enhanced secretion of E and NE, later followed by GCs released from the adrenal 
gland (Chrousos 1995, Chrousos 2009, Dhabhar 2009, Elenkov and Chrousos 1999, 
Sapolski et al. 2000). 
Psychological stressors can trigger the release of proinflammatory cytokines 
before any rise in GCs is detected (Dhabhar 2009, Sapolski et al. 2000). 
Proinflammatory cytokines are known to stimulate the stress system (HPA axis 
activation), causing the release of CRH (Baumann and Gauldie 1994, Chrousos 2009, 
Elenkov and Chrousos 1999, Sapolski et al. 2000), and peripheral CRH has been 
known to have proinflammatory actions (Elenkov and Chrousos 1999). Activation of 
the HPA axis by proinflammatory cytokines plays an important role in the negative 




from becoming detrimental to the organism: both catecholamines and GCs suppress 
the secretion of most proinflammatory cytokines (Chrousos 1995, Chrousos 2009, 
Elenkov and Chrousos 1999, Sapolski et al. 2000). It has been widely accepted that 
captivity can impose psychological stress on many animal species. Measuring 
glucocorticoids in fecal samples across time can be a valuable, non-invasive tool for 
measuring stress in many animals, including cheetahs (Keay et al. 2006).    
There is both functional (hypercortisolemia) and morphological (adrenal 
hyperplasia/hypertrophy) evidence for chronic stress among captive cheetahs, at 
levels much greater than their wild counterparts (Bolton and Munson 1999, Kӧster et 
al. 2007, Munson et al. 1999, Munson et al. 2005, Terio et al. 2004). In captivity, 
when cheetahs are moved or housed on-exhibit, they tend to show higher 
concentrations of glucocorticoids in feces than when moved or housed off-exhibit 
(Terio et al. 2004, Wells et al. 2004), and the increases observed after movement can 
persist for months (Wells et al. 2004). There is also greater daily variation in the GC 
concentrations of feces observed when cheetahs are moved on-exhibit (Wells et al. 
2004). Evidence of stress (elevated cortisol and/or behavior) being linked to anestrous 
in captive cheetahs (downregulation of the reproductive system) has also been 
demonstrated (Jurke et al. 1997, Wielebnowski et al. 2002). Hence, it appears there is 
a clear association between the captive environment and stress in cheetahs. Stress-
related hypersecretion of the proinflammatory cytokine IL-6, in addition to 
hypercortisolism, may result in the chronic upregulation of the acute phase response 
(Chrousos 2009) in cheetahs, contributing to the increase in disease and mortality 




The acute phase response (APR) is a systemic reaction that occurs early 
during inflammation, initiated by cells of the innate immune system in response to 
invading pathogens, tissue damage and associated activation signals. Macrophages 
resident in affected tissues and monocytes in the blood are the immune cells primarily 
responsible for the initiation of the APR (Baumann and Gauldie 1994, Paltrinieri 
2008). The liver is one of the primary targets for systemic inflammatory mediators 
(Baumann and Gauldie 1994, Jensen and Whitehead 1998, Paltrinieri 2008); it is the 
location of acute phase protein (APP) production (Baumann and Gauldie 1994, Cerón 
et al. 2005, Jensen and Whitehead 1998, Paltrinieri 2008). APPs, by definition, are 
proteins whose concentration in serum significantly increase or decrease during the 
APR, including C-reactive protein (CRP), serum amyloid A protein (SAA), alpha-1-
acid glycoprotein (AGP), ceruloplasmin, haptoglobin and albumin. The systemic 
inflammatory mediators generally responsible for the upregulation of CRP, SAA and 
AGP production during the APR are the IL-1 type cytokines, such as IL-1β and TNF-
α (Baumann and Gauldie 1994, Jensen and Whitehead 1998, Marhaug and Dowton 
1994, Paltrinieri 2008). Additionally, the actions of the IL-1 type cytokines on the 
production of APPs are often synergistically enhanced in the presence of IL-6 
(Baumann and Gauldie 1994, Cerón et al. 2005, Jensen and Whitehead 1998). 
The major APPs that have been identified to date in the domestic cat are SAA 
and AGP (Cerón et al. 2005, Kajikawa et al. 1999, Paltrinieri 2008). The increase in 
SAA observed in domestic cats during the APR, approximately a 10-100 fold 
increase, is lower in magnitude compared to humans and other species, but still 




Kajikawa et al. 1999). Multiple studies have shown that the SAA concentrations in 
sick domestic cats are significantly higher than the SAA concentrations in healthy 
domestic cats (Giordano et al. 2004, Kajikawa et al. 1999, Kann et al. 2012, Sasaki et 
al. 2003, Tamamoto et al. 2008).  
Transcriptional induction of the cheetah SAA1 gene is dependent on both the 
CCAAT-enhancer-binding protein beta (C/EBPβ) and nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) cis-acting elements located in the 
promoter region (Marhaug and Dowton 1994). In the presence of stimulation from 
proinflammatory cytokines, C/EBPβ and NF-κB enter the nucleus and bind to the 
promoter region of the SAA1 gene inducing transcription (Barnes and Karin 1997, 
Beg et al. 1993). IL-1β, TNF-α, and IL-6 proinflammatory cytokines have all been 
shown to stimulate hepatic SAA production during the APR (Baumann and Gauldie 
1994, Cerón et al. 2005, Jensen and Whitehead 1998, Marhaug and Dowton 1994, 
Paltrinieri 2008). 
There is a positive, synergistic effect of GCs with cytokines in the induction 
of SAA synthesis during the APR (Chrousos 1995, Dhabhar 2009, Marhaug and 
Dowton 1994). This effect is the result of the upregulation of cytokine receptors on 
the surface of hepatic cells by GCs (Baumann and Gauldie 1994, Wiegers and Reul 
1998), increasing the sensitivity of the hepatic cells to cytokine stimulation (Baumann 
and Gauldie 1994, Paltrinieri 2008, Thorn and Whitehead 2002, Wiegers and Reul 
1998). Contrastingly, it is widely accepted that the production of many 




inhibited by GCs (Baumann and Gauldie 1994, Chrousos 1995, Jensen and 
Whitehead 1998, Paltrinieri 2008, Wiegers and Reul 1998). 
The SAA protein normally has a short half-life, approximately 90 minutes in 
normal serum (Marhaug and Dowton 1994). Therefore the concentration of SAA in 
serum returns to normal following the termination of inflammation. In multiple 
species, including domestic cats, monocytes contribute to SAA degradation (Migita et 
al. 2001, Tamamoto et al. 2012). However, this is inhibited in the presence of the 
cytokines IL-1β and IFN-γ (Migita et al. 2001), and glucocorticoids (Tamamoto et al. 
2012). The amyloid A (AA) protein responsible for causing AA amyloidosis, is a 
byproduct of SAA protein degradation. AA amyloidosis is a disease induced by the 
over-accumulation and incomplete degradation of SAA and polymerization of the AA 
protein into fibrils (Marhaug and Dowton 1994), which are insoluble and get 
deposited into organs, ultimately leading to organ dysfunction and organ failure. 
Therefore, chronic systemic inflammation can result in the persistent upregulation of 
SAA production, a decrease in SAA degradation, and an accumulation of SAA 
protein in the serum, providing evidence that it plays a role in amyloid A (AA) 
amyloidosis pathogenesis.  
Systemic AA amyloidosis is an increasingly important cause of morbidity and 
mortality in captive cheetahs (Munson et al. 2005, Ofri et al. 1997, Papendick et al. 
1997). The number of cases of systemic amyloidosis in captive cheetahs has 
increased over time from 20% of individuals in pre-1990 necropsies to 70% of 
individuals in 1995 (Papendick et al. 1997). Amyloid deposition can be observed in 




stomach, intestine, lymph node, heart, pancreas and esophagus (Chen et al. 2012, 
Munson et al. 1999, Papendick et al. 1997). Most commonly, amyloid deposition is 
observed in the kidneys, and renal failure is the sole or partial cause of death in 74% 
of cheetahs with amyloidosis, compared to only 20% of cheetahs without amyloidosis 
(Papendick et al. 1997).  
The aim of this study was to investigate the potential effects of stress (due to 
captivity) and inflammation on serum concentrations of SAA protein that may be 
linked to AA amyloidosis pathogenesis, in order to gain a better understanding of the 




 Cheetahs from two captive populations and one wild population are 
represented in this study. The captive Smithsonian population (NZP-SCBI) is 
comprised of cheetahs housed at either the National Zoological Park (NZP) in 
Washington, DC, or the Smithsonian Conservation Biology Institute (SCBI) in Front 
Royal, VA. Cheetahs at the NZP are on-exhibit to the public approximately 10-12 
hours per day, 7 days a week. The SCBI is not open to the public, and thus these 
cheetahs are off-exhibit. Enclosure sizes at both facilities are <0.5 acres. All of these 
cheetahs were born in captivity. 
 The captive Cheetah Conservation Fund (CCF) population is located near 
Otjiwarongo, Namibia. These cheetahs were all born in the wild and housed in 




“problem” animals trapped by farmers. Some of these cheetahs will remain captive 
for the remainder of their life, while others may be released back into the wild, 
depending on individual circumstances. CCF cheetahs are kept in a variety of 
different types of enclosures. Cheetahs with no chance of being released are held in 
smaller enclosures (approx. 2 acres) at the center of CCFs main buildings, including 
an office, education center, gift shop and café, etc. These cheetahs are on-exhibit to 
the public, including being exercised on a lure system for visitors and fed in front of 
the public daily. Some of these cheetahs have been raised as ambassador animals and 
have frequent human contact with their handlers and can be walked on leashes 
outside of their enclosures. Other cheetahs at CCF are housed in large (>10 acres) 
“drive-thru safari” type enclosures. These cheetahs are “retired” from the most public 
enclosures, therefore previously habituated to humans. They are not exercised or fed 
in front of the public, but are exposed to multiple “drive-thrus” per day, where safari 
trucks seek out the animals for tourists to take photographs.  
 CCF also houses several cheetahs away from the public, many of which have 
a high probability of being released to the wild. Some of these animals are exercised 
regularly by chasing the feeding truck, but some are not due to physical constraints. 
One of these enclosures is quite large (>100acres), which houses the wildest females 
to be released.  
CCF also has a “soft-release camp”. This is a former game ranch (approx. 
10,000 acres) that includes many game species (oryx, kudu, hartebeest, eland, etc.) as 
well as a low density of predators (hyena, leopard). Cheetahs to be released to the 




sources and hunt successfully, without too much pressure from predators. If a cheetah 
proves to be successful, CCF finds an appropriate location for them to be 
reintroduced to the wild. 
The third population studied included wild cheetahs in Namibia whose home 
range was close to, or included, CCF central property and surrounding farmland.  All 
of these cheetahs were male and made up three coalitions. These individuals were 
chosen because multiple fecal samples per individual were able to be collected and 
identified, and several (two coalitions) were previously captured and medically 
examined by CCF staff, providing an opportunity for blood sampling.   
Sample Collection 
Fecal samples were obtained from cheetahs at the Smithsonian Conservation 
Biology Institute (SCBI) in Front Royal, VA (N=17), and National Zoological Park 
(NZP) in Washington, DC (N=4). Samples were collected approximately every 2 or 3 
days over three consecutive months resulting in 36-50 samples per cheetah. Serum 
samples were also obtained from 20 of the 21 cheetahs. Similarly, fecal samples were 
also obtained from cheetahs at the CCF in Namibia. Samples from wild-born, captive 
cheetahs (N=34) were collected every 1 or 2 days over three consecutive weeks, 
resulting in 7-15 samples per cheetah. Cheetahs housed together were fed insoluble 
markers such as uncooked corn, lentils, oats, rice or colored glitter in order to identify 
ownership of fecal samples. 
Fecal samples were also obtained from wild cheetahs (N=7: 1-15 samples per 
cheetah) and cheetahs in “soft-release” (N=14: 1-9 samples per cheetah) as available. 




Serum samples were obtained for all of the captive cheetahs, 4 of 7 wild 
cheetahs, and 6 of 14 cheetahs in “soft-release”. For a complete list of sample 
numbers per individual, see Appendix II.  
Hormone extraction from fecal samples 
Fecal cortisol and associated metabolites were obtained from samples using an 
ethanol/methanol extraction procedure. Samples were first lyophilized, pulverized 
and approximately 0.2g of powdered feces was shaken for 30 minutes in 5ml of 
ethanol (90%). Samples were centrifuged at 1500 x g for 20 min, then supernatant 
was recovered and the pellet resuspended in 5ml of ethanol (90%), shaken for 1 min 
and re-centrifuged. Ethanol supernatants were combined and dried down completely 
under air. Extracts were reconstituted in 3ml ethanol (100%), vortexed briefly, 
sonicated for 15 min, and dried down completely under air. Extracts were next 
reconstituted in 1ml methanol (100%), vortexed briefly, sonicated for 15 min, and 
dried down completely under air. Extracted samples were finally reconstituted in 1ml 
PBS (“neat” sample). Recovery of 3H-cortisol added to fecal samples before 
extraction was calculated, and the extraction procedure was repeated for any samples 
in which recovery did not exceed 60%. Samples were stored at -20 ºC until analyzed. 
Quantification of cortisol in serum and fecal hormone extracts 
Serum samples and fecal hormone extracts were diluted 1:25 and 1:20, 
respectively, in PBS before analysis. Samples were analyzed in duplicate using a 
competitive enzyme-linked immunosorbent assay (ELISA) previously validated for 




antibody and associated horseradish-peroxidase (HRP) ligand. The EIA was validated 
for use with cheetah serum samples based on parallelism (Figure 4.1; 3.90–1000 
pg/well; r=0.99532, P<0.0001 and r=0.99356, P<0.0001, for cheetahs 114799 and 
114680 with standard, respectively). Fecal hormone extract samples with percent 
binding of Cort-HRP above 80% were re-analyzed without dilution (“neat” sample). 
Samples with percent binding of Cort-HRP below 20% were re-diluted an additional 
10-fold and re-analyzed. The inter-assay coefficients of variation (CV) for two 
internal controls (n=69 assays) were 8.9% and 12.2%, and the intra-assay CV was 
<10%.  
Protein extraction from fecal samples 
To maximize the amount of serum amyloid A protein and its byproducts 
extracted from fecal samples while eliminating other proteins, a method adapted from 
Pras’ method (1968) was used. Fifty milligrams of dried, pulverized feces was 
measured into a 2ml microcentrifuge tube. A salt solution, 0.15M NaCl, was used to 
eliminate saline soluble proteins from the sample by adding 1ml to the 
microcentrifuge tube, mixing the sample for 5 mins on a vortexer, centrifuging the 
tube for 10 mins at 15,000 x g, and then decanting the supernatant. This was repeated 
six additional times. Saline supernatants were discarded. Samples were then washed 
by the addition of 1ml diH2O to the sample, mixing the sample for 5 mins on a 
vortexer, centrifuging the tube for 10 mins at 15,000 x g, then pipetting a fixed 
amount of supernatant (800μl) from the sample. This was repeated two times with 



























diH2O and removal of 500μl, then a single step with the addition of 500µl diH2O and 
removal of 700µl. The final centrifuge spin was done at full speed for the table top 
centrifuge (approximately 21,000 x g). Because amyloid proteins are water soluble, 
diH2O supernatants were collected and pooled for a total of 4 ml collected. 
Quantification of total protein in fecal protein extracts  
 Total concentration of protein in fecal protein extracts was quantified using 
the Bio-Rad Protein Assay kit, utilizing the protocol for the microassay procedure. 
Concentrations of β-amyloid (Aβ) [1-40] human protein (Novex®; Invitrogen Cat 
No. 03-136) ranging from 1.875 – 8.75 µg/ml was used as a standard for the assay.  
Quantification of serum amyloid A protein in serum and fecal protein extracts  
Serum amyloid A concentration was measured in serum and fecal protein 
extract samples using the PhaseTM Range Multispecies SAA ELISA kit (Tridelta 
Development Ltd: Cat No. TP 802). Serum samples were diluted 1:100 in the 
provided sample diluent before use. Anti-SAA/HRP conjugate (50µl) and 
sample/control/standard (50µl, in duplicate) were added to each pre-coated well and 
incubated for 1.5 hours on a shaker at room temperature. After washing, 100µl of 
TMB substrate solution was added to each well and the plate was incubated for 15 
minutes at room temperature. Stop solution was added (100µl) and absorbance for 
each well was read at 450nm using 620nm as a reference. A subset of the data 
collected from serum samples was previously reported in Chapter 2. The inter-assay 





Quantification of proinflammatory cytokines (TNF-α, IL-1β, IL-6) in serum  
Feline DuoSet® ELISA kits (R&D Systems) for TNF-α, IL-1β, and IL-6 were 
used following the manufacturer’s instructions (validated in Chapter 3) to quantify 
the concentration of the cytokines in the cheetah serum samples. Samples were 
diluted 1:2 in PBS (with 1% BSA) before TNF-α and IL-1β assays. Samples were 
diluted 1:10 in PBS (with 1% BSA) before IL-6 assays. The inter-assay CV for two 
internal controls (n=5 assays) for TNF-α were 12.9% and 15.3%.  The inter-assay CV 
for two internal controls (n=5 assays) for IL-1β were 3.3% and 4.5%.  The inter-assay 
CV for two internal controls (n=5 assays) for IL-6 were 7.3% and 9.5%.   
Univariate statistical analyses 
 Five variables were calculated from the cortisol concentrations quantified 
from fecal extracts: average cortisol (average), baseline cortisol (baseline), total 
cortisol variation (cortSTD), cortisol variation around baseline only (cortSTDbase), 
and frequency of cortisol peaks per sample collected (cortPEAKS). Average cortisol 
is the arithmetic mean of cortisol across all samples collected for an individual. 
Baseline was calculated using an iterative process that eliminates samples with high 
or low values if they fall outside the 95% confidence interval for the mean. After 
samples are removed, iterations continue until no more samples fall outside of the 
95% confidence interval. Due to low sample numbers, particularly for captive 
cheetahs at CCF and wild cheetahs, an additional step in which samples were 
eliminated to create a balance of 50% of the remaining samples falling above and 
50% of samples falling below baseline was employed. CortSTD is the standard 




deviation of only the samples used in calculation of baseline cortisol. Cortisol peaks 
were determined as samples that were outside of the 95% confidence interval based 
on the baseline cortisol and cortSTD. Peaks were standardized per the number of 
fecal samples collected for an individual such that cortPEAKS = number of peaks / 
total number of samples. See Figure 4.2 for a representative cortisol profile from 
individual 114382. Cheetah 1340 was determined to be an outlier (extreme high 
values) and excluded from the analysis for baseline cortisol, average cortisol, 
cortSTD and cortSTDbase. 
 The five cortisol variables were analyzed using PROC MIXED of SAS 
Enterprise Guide (version 6.1) with the Kenward and Roger (DDFM=KR) option for 
adjustment of denominator degrees of freedom, including age as a covariate, status 
(captive, wild or soft-release), population (Namibia or North America), and sex 
(male/female) as fixed categorical factors and assuming heterogeneous variances for 
the status*population*sex groupings. Effects of status, population and sex were 
determined using a set of non-orthogonal contrasts due to the incomplete factorial 
nature of the status*population*sex groupings.  
 Total protein content of fecals and SAA concentration in fecals were analyzed 
using the same statistical model and contrasts as the previous cortisol variables, 
except the covariate age was excluded due to the lack of a significant relationship 
with the response variables. Total protein was included as a covariate in the analysis 
for SAA concentration. 
 SAA concentration in serum was log (base 10) transformed before analysis 















Figure 4.2 Representative profile for cortisol across a three month collection period 









concentrations were also analyzed using the same statistical model and contrasts as 
the fecal variables excluding the covariate age, again due to a high lack of a 
significant relationship with the response variables. IL-6 concentrations were 
similarly analyzed assuming homogeneous variances. Cheetah 114681 was 
determined to be an outlier (extreme high values) and excluded from the analysis for 
TNF-α and IL-1β. 
The effect of environmental factors on average cortisol, baseline cortisol, 
cortSTD, cortSTDbase, log10[SAA], [TNF-α], and [IL-1β] within the captive CCF 
population was also examined. Environmental factors included exposure to humans 
(High: “on-exhibit” or frequent exposure; Low: “off-exhibit” or sees few individuals, 
few times a day), regular exercise (Yes: 1+ times per week; No: <1 time per week), 
and enclosure size (Large: >10 acres; Small: <10 acres). Based on these criteria, 
cheetahs were separated into 6 groups. The fecal variables were analyzed using 
PROC MIXED of SAS Enterprise Guide (version 6.1) including age as a covariate, 
and human exposure, exercise, and enclosure size as fixed categorical factors. Effects 
of human exposure, exercise, and enclosure size were determined using a set of 
orthogonal contrasts due to the incomplete factorial nature of the groupings. 
Statistical significance between groups was declared at α=0.10.  
The effect of environment on average cortisol, baseline cortisol, cortSTD, 
cortSTDbase, [log10SAA], [TNF-α], and [IL-1β] within the captive Smithsonian 
population was also examined. Using the above classifications, cheetahs made only 
two groups determined by location, thus cheetahs held at NZP were compared versus 




Correlation analyses were used to determine the relationships between all 
variables measured in the fecal and serum samples, both across populations and 
within each captive population (NZP-SCBI and CCF). Within population correlations 
for the wild and soft-release cheetahs were not performed due to insufficient sample 
size. 
Multivariate statistical analyses 
 
 AA amyloidosis status of the cheetahs measured in this study is unknown. 
Therefore, a multivariate statistical approach (canonical discriminant analysis: CDA) 
was taken to investigate how population differences across the multiple correlated 
variables measured can distinguish the populations from each other. CDA is a process 
that defines independent linear combinations of variables (canonical discriminant 
functions: CDFs) that maximize the differences between the groups. The DISCRIM 
procedure in SAS Enterprise Guide (version 6.1) with parametric, linear classification 
rules, and prior probabilities proportional to sample sizes was used to perform both 
descriptive and predictive canonical discriminant analyses (DDA and PDA, 
respectively). “Soft-release” cheetahs were excluded from this analysis due to 
missing values for too many individuals.  
DDA was used to separate the populations of cheetahs (CLASS variables: 
NZP-SCBI, CCF, and Wild). Independent variables included in the analysis were 
average cortisol, baseline cortisol, cortSTD, cortSTDbase, log10[SAA], [TNF-α], and 
[IL-1β]. Within-group covariance matrices were used as the basis of the measure of 




 For PDA, a model was constructed to predict population membership based 
on the CDFs. Resubstitution and cross-validation (also known as jackknifing) 
methods were used to evaluate the performance of the discriminant model (Huberty 
1994). 
Results 
Fecal cortisol and associated metabolite concentrations and variability between 
populations 
 Captive cheetahs at Smithsonian facilities have higher baseline cortisol, higher 
average cortisol and greater daily variation in cortisol (both cortSTD and 
cortSTDbase) when compared to captive cheetahs at CCF (P<0.0005; Figure 4.3A). 
Differences between male and female cheetahs in captivity was only detected for 
cortSTD: captive females have greater overall variation in cortisol compared to 
captive males (P=0.0581; Figure 4.3B). Cheetahs put into “soft-release” at CCF have 
significantly higher baseline and average cortisol compared to captive cheetahs at 
CCF (P<0.05; Figure 4.3C). The only difference detected between males and females 
in “soft-release” was in variation around baseline: females showed less variability 
around baseline compared to males (P=0.0393; Figure 4.3E). Due to the limitation of 
having only male wild cheetahs sampled, wild cheetahs were compared to male 
captive and “soft-release” cheetahs at CCF. Wild males have significantly higher 
baseline cortisol, average cortisol, and greater variation around baseline 
(cortSTDbase) than captive male cheetahs (P<0.05; Figure 4.3D). There were no 





Figure 4.3. Fecal cortisol and associated metabolite concentrations by population. 
Means ± SEM are presented. a,bDesignate significant differences between groups 





release” (Figure 4.3E). No differences between any populations were detected for 
cortPEAKS. 
Population differences in fecal protein concentrations  
 Wild male cheetahs have significantly higher protein content in feces 
compared to captive male cheetahs at CCF (P=0.0536; Figure 4.4A). Similarly, 
cheetahs in “soft-release” have significantly higher protein content in feces compared 
to captive cheetahs (P=0.0051l, Figure 4.4A). The only significant difference 
observed in SAA content in feces was between captive cheetahs at CCF vs. NZP-
SCBI: significantly more SAA was detected in the feces of CCF cheetahs (P=0.0002; 
Figure 4.4B). 
Cortisol and serum amyloid A protein concentrations in serum 
 Though there was no difference in the serum concentrations of cortisol 
between captive cheetahs at CCF and captive cheetahs at NZP-SCBI (Figure 4.5A), 
female cheetahs in captivity have significantly higher serum cortisol concentrations 
compared to male cheetahs in captivity (P=0.0214; Figure 4.5B). Female cheetahs in 
“soft-release” had significantly lower cortisol concentrations in serum than captive 
CCF females (P=0.001: Figure 4.5C). There was no difference in serum cortisol 
concentrations between captive male cheetahs at CCF and wild males (Figure 4.5D). 
 The log10SAA concentration in serum was significantly different between 
captive cheetahs at CCF and captive cheetahs at NZP-SCBI. Captive cheetahs at both 
the NZP and SCBI have significantly higher log10SAA concentrations in serum 







Figure 4.4. Total protein and serum amyloid A protein concentrations in feces by 
population. Means ± SEM are presented. *Denotes a significant difference between 
two populations, P=0.0536. **Denotes a signficant difference between populations 
















Figure 4.5. Differences in serum cortisol concentrations (lsmeans ± SEM) across 
cheetah populations. a,bDesignate significant differences between groups based on 



















Figure 4.6. Comparison of serum log10SAA concentrations (lsmeans ± SEM) across 
populations. *Denotes a significant difference between two populations, P=0.0156. 









increase in log10SAA concentrations compared to captive females at CCF (P=0.0156; 
Figure 4.6). There was no significant difference between captive CCF cheetahs and 
wild cheetahs (Figure 4.6). 
Population differences in proinflammatory cytokine (TNF-α, IL-1β, IL-6) 
concentrations in serum  
 For both TNF-α and IL-1β, wild cheetahs as well as “soft-release” and captive 
cheetahs at CCF had significantly higher cytokine concentrations in serum compared 
to captive cheetahs at NZP-SCBI (P<0.0001; Figure 4.7). Analyzing the results of the 
IL-6 assay is not appropriate, as all samples assayed fell between zero and the lowest 
standard. Thus all concentrations were determined based on extrapolation of the data. 
Additionally, it appears all concentrations are likely overestimated after they were 
multiplied by 10 for the dilution factor used considering the relative abundances of 
the three cytokines after LPS stimulation (Chapter 3). Nonetheless, there was a 
significant difference in IL-6 concentrations in serum between wild males and captive 
male cheetahs at CCF: wild males had significantly higher IL-6 concentrations 
(P<0.0001). There was no significant differences detected in IL-6 concentrations 
between “soft-release”, captive CCF and captive NZP-SCBI populations. 
Environmental associations with cortisol, inflammation, and SAA protein within 
captive populations 
 Among cheetahs at CCF, higher baseline and average cortisol concentrations 
were found to be associated with high exposure to humans and small enclosures 













Figure 4.7. TNF-α and IL-1β cytokine concentrations in cheetah serum (lsmeans ± 
SEM) across populations. a,bDesignate significant differences between groups based 


















Figure 4.8. Effects of environmental factors on baseline and average cortisol 
concentrations in feces among captive cheetahs at Cheetah Conservation Fund. 















captive environments. Similarly, higher serum concentrations of log10SAA and IL-1β 
were associated with small enclosures (P=0.019 and P=0.0413, respectively). TNF-α 
concentrations did not differ between captive environments. There were no 
significant differences between cheetahs held at the two different Smithsonian 
locations (NZP and SCBI) for any of the variables examined, however 
proinflammatory cytokines TNF-α and IL-1β were marginally higher in cheetahs on-
exhibit at NZP versus off-exhibit at SCBI (P=0.0527 and P=0.1208, respectively). In 
general, values for log10SAA and cortisol variables for the NZP-SCBI cheetahs most 
closely resembled those of CCF cheetahs in small enclosures, without regular 
exercise and high exposure to humans (Figure 4.9). 
Variable correlations across populations 
 Baseline cortisol, average cortisol, cortSTD and cortSTDbase are significantly 
positively correlated with one another (P≤0.0002; Table 4.1). CortPEAKS was 
significantly positively correlated with average cortisol and cortSTD only (P≤0.0003; 
Table 4.1), which is logical since all cortisol peaks are included in the calculation of 
these variables, yet removed from the calculation of baseline cortisol and 
cortSTDbase. Proinflammatory cytokines TNF-α, IL-1β and IL-6 were all 
significantly positively correlated in serum (P≤0.0035; Table 4.2). There were no 
significant correlations between cortisol variables measured in fecals (baseline 
cortisol, average cortisol, cortSTD, cortSTDbase, and cortPEAKS) and variables 




Figure 4.9. Population comparison of baseline and average cortisol in feces (A) and 
log10SAA concentration in serum (B) across captive cheetah populations and 
environments. Means among CCF groups that do not share a letter are significantly 
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CortPEAKS      1.0 
 
Table 4.1. Cortisol variable correlation coefficients (r) across all cheetah populations.  
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Log10SAA      1.0 
 
Table 4.2. Serum variable correlation coefficients (r) across all cheetah populations.  













Variable correlations within populations  
 When variable correlations were examined independently by population, a 
significant positive relationship between age and cortisol in feces was detected for 
baseline cortisol, average cortisol, cortSTD, and cortSTDbase among CCF cheetahs, 
and for average cortisol and cortSTDbase among NZP-SCBI cheetahs (P<0.05; Table 
4.3). In contrast, age was not associated with any variables measured in serum (Table 
4.4). Log10SAA concentration was positively correlated with IL-6 in CCF cheetahs 
only (P=0.0468; Table 4.4). Log10SAA concentration was positively correlated with 
cortSTD and cortSTDbase in NZP-SCBI cheetahs only (P<0.05; Tables 4.5 and 4.6). 
A false significant association between IL-1β and baseline cortisol was detected in the 
NZP-SCBI cheetah population due to cheetah 114701 having both the highest 
baseline cortisol and IL-1β concentration in serum. When cheetah 114701 was 
removed from the analysis, the relationship between the two variables was no longer 
significant.   
Descriptive Discriminant Analysis 
 Two significant canonical discriminant functions (Can1 and Can2) were 
produced that defined the underlying dimensions in the data that explained the 
differences between the three populations (NZP-SCBI, CCF and wild cheetahs). Can1 
explained over 71% of the total variation among the three populations and best 
defined the difference between NZP-SCBI cheetahs and Namibian cheetahs (captive 
and wild). Can2 explained the remaining variation between the populations and best 




















under H0: ρ=0 









































































Table 4.3. Cortisol variable correlation coefficients (r) within captive cheetah 
populations. CCF cheetahs are highlighted in orange. NZP-SCBI cheetahs are 




















under H0: ρ=0 









































































Table 4.4. Serum variable correlation coefficients (r) within captive cheetah 
populations. CCF cheetahs are highlighted in orange. NZP-SCBI cheetahs are 
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Table 4.5. Correlation coefficients (r) of cortisol variables measured in feces with 
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Table 4.6. Correlation coefficients (r) of cortisol variables measured in feces with 
serum variables within the NZP-SCBI captive cheetah population. Significant 

















Figure 4.10. The three populations of cheetahs included in the canonical discriminant 
analysis (NZP-SCBI, CCF, and Wild) can be discriminated with 76.8% accuracy 
based on the two canonical discriminant functions calculated (Can1 and Can2). 
Individual animals are plotted based on their canonical discriminant function scores 








The total canonical structure (the correlation coefficients between the 
individual variables and the canonical scores) is presented in Table 4.7. Log10SAA 
concentration was significantly positively correlated with Can1 (P<0.0001), which 
had similar positive correlations with baseline cortisol, average cortisol, and 
cortSTDbase, and was negatively correlated with IL-1β and TNF-α. Log10SAA 
concentration was not associated with Can2. Can2 was positively correlated with 
baseline cortisol, average cortisol, cortSTDbase, cortSTD, as well as IL-1β and   
TNF-α concentrations. 
Predictive Discriminant Analysis  
When resubstitution was used to evaluate the performance of the discriminant 
model, 51 out of 56 cheetahs were classified correctly, resulting in a total error-count-
estimate of 8.93%. The 5 misclassified cheetahs were all CCF cheetahs that were 
misclassified as NZP-SCBI cheetahs. When the cross-validation method was used, 43 
out of the 56 cheetahs were classified correctly, resulting in a total error-count-
estimate of 23.21%. All four wild cheetahs were misclassified as CCF cheetahs. 
Because only 3 wild cheetahs are used to generate the discriminant model created in 
each iteration, the amount of information about wild cheetahs is very limited and 
individual differences can make large changes to the model. Thus, it is unsurprising 
that the individual left out during any given iteration was always misclassified. Also 
when using the cross-validation method, 6 CCF cheetahs were misclassified as NZP-
SCBI cheetahs and 3 NZP-SCBI cheetahs were misclassified as CCF cheetahs. There 















Pearson Correlation Coefficients (r) 
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Table 4.7. Total canonical structure indicating correlation coefficients (r) between 





Previous work done by Terio et al. (2004) and Munson et al. (2005) has 
suggested that the high prevalence of gastritis and AA amyloidosis observed in 
captive cheetahs in North America is likely related to the stress associated with being 
in captivity. In this study it was shown that the captive Smithsonian population of 
cheetahs has significantly higher levels of cortisol compared to the captive CCF 
population. In contrast to the previous studies, wild cheetahs demonstrated equally 
high levels of cortisol as the captive Smithsonian population. It is not entirely 
unexpected that wild cheetahs have higher baseline cortisol and cortSTDbase 
compared to CCF cheetahs, because there was less statistical power to declare 
samples as acute stress peaks and eliminate them from the calculations. Also, one 
may expect the wild environment to be more unpredictable in terms of food 
availability, hunting success and the presence of predators, which may cause more 
frequent acute stress peaks and thus higher average cortisol and cortSTD. Cheetahs 
defecate approximately once per day, therefore any diurnal fluctuations in cortisol 
due to circadian secretory patterns are attenuated in feces (Keay et al. 2006). 
It is also possible that seasonal changes in cortisol are affecting the data. 
When wild cheetah samples are averaged by month, it seems clear that there is an 
increase in cortisol from September to November, which is the end of the winter 
season when food and water is most scarce (Figure 4.11). This corresponds to periods 
of anestrous observed in captive Namibian females between August and December in 
a previous study during a particularly dry winter (Terio et al. 2003). Studies among 
















Figure 4.11. Fecal cortisol concentrations in wild cheetahs (N=7) by month. 






are positively correlated with glucocorticoid concentrations (Busch and Hayward 
2009) and that moderately elevated glucocorticoids can actually be related to 
increased survival in the wild for some species (Busch and Hayward 2009, Dhabhar 
2009). Also, cheetahs that were previously held captive at CCF and subsequently put 
into “soft-release” had similarly high levels of cortisol. Considering these factors, it is 
likely that even though wild cheetahs were not found to have statistically significant 
differences in measures of stress, that their stress is more acute or seasonal in nature 
and does not affect these animals the same as the chronic levels of stress seen in the 
North American captive cheetah population in this and previous studies (Bolton and 
Munson 1999, Munson et al. 1999, Munson et al. 2005, Terio et al. 2004).  
The ELISA assay for SAA protein concentrations in fecal protein extracts was 
tested as a non-invasive tool for monitoring amyloid fibril deposition in feces, as seen 
in cheetahs with moderate to severe amyloidosis (Zhang et al. 2008). The idea for its 
use was based on the assumption that the antibody used in the assay binds the most 
conserved region of the SAA protein across species, which is retained as part of the 
AA protein (Johnson et al. 1997), thus it may be an indirect measurement of amyloid 
fibril accumulation in feces. The only statistical difference found in fecal SAA 
concentrations was between captive cheetahs at CCF and captive NZP-SCBI 
cheetahs, and though significant, it does not appear to be biologically relevant as the 
difference between the populations was small and it is uncorrelated with log10SAA 
concentrations in serum. Therefore, it was concluded that fecal SAA protein 
concentrations would not be a good way to assess possible amyloid fibril deposition 




Overall protein concentrations in feces were significantly higher in wild and 
“soft-release” cheetahs compared to captive cheetahs. This difference seems likely 
due to differences in diet, as captive cheetahs are fed supplemented muscle meat 
either on or off the bone (CCF and NZP-SCBI, respectively), whereas wild and “soft-
release” cheetahs are eating whole carcasses, including bits of hair and hide that 
provide additional fiber in the diet and likely increase diet digestibility, as well as 
internal organs, such as heart and liver, that increase the concentration of protein in 
the diet. Whether dietary differences have an effect on amyloidosis pathogenesis has 
not been investigated. 
Log10SAA concentrations in serum were significantly higher in the NZP-
SCBI captive population compared to captive CCF and wild cheetahs. This is 
expected given previous research showing that AA amyloidosis among cheetahs in 
captivity is exceedingly common in North America, yet exceptionally rare in wild 
cheetahs (Munson et al. 2005). Furthermore, studies in humans have found elevated 
SAA concentrations in serum to correlate with AA amyloidosis (Biran et al. 1986, 
Lachmann et al. 2007, Marhaug and Dowton 1994). Wild cheetahs appeared to have 
lower log10SAA concentrations compared to captive CCF. However, this difference 
could not be declared statistically significant, likely due to the small sample size for 
wild cheetahs. Therefore, it appears that SAA concentrations in serum of cheetahs is 
similarly correlated with the probability of developing AA amyloidosis. 
Previous work in humans has shown that amyloid deposits can regress and 
organ function can recover if SAA concentrations are controlled (kept low) (Gillmore 




(ASO) has been shown to reduce SAA concentration in mice, particularly by 
facilitating a more rapid return to baseline after episodic bursts in SAA concentration 
(Kluve-Beckerman et al. 2011).  SAA-specific ASOs were also shown to reduce 
amyloid deposition in treated mice in which amyloidosis was previously induced 
(Kluve-Beckerman et al. 2011). Whether ASOs could be a therapy to treat systemic 
amyloidosis in either humans or cheetahs has yet to be investigated.  
Papendick et al. (1997) found that all cheetahs diagnosed with amyloidosis 
also suffered from other significant chronic inflammatory diseases in organs other 
than kidney, most commonly chronic lymphoblastic gastritis. Thus, it appears the 
high prevalence of AA amyloidosis among captive cheetahs is related to chronic 
inflammation. Knowing that almost 100% of captive cheetahs in North America have 
gastritis (a chronic inflammatory condition) to some degree (Munson 1993, Munson 
et al. 1999, Munson et al. 2005), it was expected that proinflammatory cytokine 
concentrations would be higher in the captive NZP-SCBI population compared to the 
other cheetah populations. In fact, the opposite was observed in this study. TNF-α and 
IL-1β were significantly lower in the NZP-SCBI cheetah population compared to the 
other cheetah populations. Aside from the mean concentrations of proinflammatory 
cytokines, worth noting is the differences in the range of concentrations observed for 
each population. The range of concentrations within the captive NZP-SCBI 
population was much smaller compared to CCF and wild cheetah populations (Table 
4.8). It is possible that captive NZP-SCBI cheetahs are not often exposed to new 
pathogens or are less likely to incur injuries such that they have low proinflammatory 























TNF-α NZP-SCBI 9.67 90.42 
 CCF (captive) 14.63 956.27 
 CCF (soft-release) 26.89 934.02 
 Wild 247.22 1661.04 
IL-1β NZP-SCBI 15.61 121.10 
 CCF (captive) 25.76 1822.81 
 CCF (soft-release) 33.05 856.20 
 Wild 321.05 1657.62 
Table 4.8. Minimum and maximum proinflammatory cytokine concentrations 




post-surgery and even this individual did not show elevated cytokines. Therefore, 
these results may be indicative of dysregulation of the immune system and 
suppression of the production of proinflammatory cytokines in captive NZP-SCBI 
cheetahs due to a chronic elevation of glucocorticoids.  
Glucocorticoids induce the transcription of IκBα protein (Auphan et al. 1995, 
Barnes and Karin 1997, Scheinman et al. 1995). Without stimulation signaling,     
NF-κB is bound to IκBα or IκBβ in the cytoplasm of the cell and is prevented from 
entering the nucleus (Barnes and Karin 1997, Beg et al. 1993). However, in the 
presence of stimulation from proinflammatory cytokines, such as TNF-α (Beg et al. 
1993, Scheinman et al. 1995) and IL-1β (Barnes and Karin 1997), IκBs are 
phosphorylated, disassociate from NF-κB, and get degraded (Barnes and Karin 1997, 
Beg et al. 1993). The unbound NF-κB enters the nucleus and binds to the promoter 
region of target genes associated with inflammatory and immune responses, including 
many proinflammatory cytokines (Barnes and Karin 1997, Beg et al. 1993).  
Multiple studies have shown that IκBα synthesis is increased in the presence 
of dexamethasone (DEX: a synthetic glucocorticoid), causing fast reassociation of 
NF-κB with IκBα, thus reducing the translocation of NF-κB to the nucleus, even 
under cytokine stimulation (Auphan et al. 1995, Scheinman et al. 1995). This 
inhibitory effect of DEX is mediated through cytoplasmic glucocorticoid receptors 
(Auphan et al. 1995), with possible direct protein-protein interaction between the 
glucocorticoid receptor (GR) and NF-κB (Barnes and Karin 1997). Therefore, 
activated GRs are involved in blocking transcription factors required for the 




that the expression of many cytokines (including TNF-α, IL-1β and IL-6) is inhibited 
by GCs (Baumann and Gauldie 1994, Chrousos 1995, Jensen and Whitehead 1998, 
Paltrinieri 2008, Wiegers and Reul 1998). Therefore, determining the role of 
inflammation in AA amyloidosis pathogenesis in the captive North American cheetah 
population, in the presence of high GC concentrations, will require a more complete 
look at systemic immune regulation and the permissive vs. suppressive effects of GCs 
on immune function. It is interesting to note that among the captive CCF population, 
which had significantly lower cortisol, that IL-6 was positively correlated with 
log10SAA concentrations, suggesting that in the absence of chronically elevated GCs, 
proinflammatory cytokines do play an important role in the amount of SAA 
produced, as expected. 
Using a canonical discriminant analysis allowed the investigation of the 
relationship between the stress variables, proinflammatory cytokine concentrations 
and SAA protein concentrations simultaneously. This analysis revealed that the stress 
variables best discriminate the NZP-SCBI captive population from the captive CCF 
population along the same axis significantly associated with log10SAA 
concentrations.  Therefore, based on this analysis it can be predicted that captive 
individuals with greater levels of stress will have an increased risk of developing AA 
amyloidosis. This is supported by the significant positive correlation between 
cortSTD and log10[SAA] in the NZP-SCBI population. Whether this association is a 
direct relationship between the role of GCs in the induction of SAA production 
during the APR or indirectly through other associated mechanisms is unknown. 




compared to male captive cheetahs across both captive populations, which suggests 
that females may have an increased probability of developing AA amyloidosis, 
though a previous study declared that there is no association between the occurrence 
of amyloidosis and sex (Papendick et al. 1997).  
Worth noting is the lack of correlation observed between serum cortisol 
concentrations and cortisol concentrations in feces. The lack of correlation was likely 
due to the timing of sample collection as well as the effect of sample collection itself. 
The majority of serum samples used in this study were not collected during the same 
time period as fecal sample collection. This is the result of using only opportunistic 
serum sample collection methods, such that an individual had to be under anesthesia 
for a purpose unrelated to this study for a sample to be collected. An effort was made 
to minimize the time between serum and fecal sample collection to minimize the 
effect on the data. For several of the male cheetahs, serum was collected during an 
anesthesia for electroejaculation procedures. Depending on the time during the 
anesthesia the serum sample was collected, cortisol concentrations may have been 
affected by the procedure itself, as described in Wildt et al. (1984). Also, it is possible 
that the method of capture and/or drugs used for anesthesia can affect serum cortisol 
concentrations. Therefore, any differences in these factors between animals or 
facilities can add a lot of variability to the serum cortisol concentration data. These 
effects may also explain the lack of correlation observed between serum cortisol 
concentrations and the other variables measured in serum: proinflammatory cytokine 




The captive CCF cheetah population provides the opportunity to begin to 
investigate the possible relationships between environmental factors such as exposure 
to humans, exercise or enclosure size with stress, inflammation and SAA protein 
concentrations, due to the size of the property and the various enclosures the cheetahs 
are kept in. The stress level of cheetahs included in this study appeared to be affected 
by both enclosure size and the frequency of human exposure, such that animals in 
small enclosures and animals exposed to a lot of people (on-exhibit) had higher 
cortisol concentrations in feces. This agrees with previous work demonstrating that 
when cheetahs are moved or housed on-exhibit, they tend to show greater levels of 
stress (higher GC concentrations) than when moved or housed off-exhibit (Terio et al. 
2004, Wells et al. 2004) and the increases observed after movement can persist for 
months (Wells et al. 2004).  
Similarly, cheetahs in smaller enclosures had significantly higher log10SAA 
concentrations than cheetahs kept in larger enclosures. When enclosure size is 
considered continuous (in lieu of small vs. large), log10[SAA] decreases by 
0.008ng/ml for every additional acre of enclosure space. Therefore, to get effective 
decreases in log10[SAA] will require significant increases in enclosure size, which are 
likely unattainable at North American institutions.  
Exercise also decreased log10[SAA], however this effect was dependent upon 
the other environmental factors, such that it only occurred among cheetahs kept in 
small enclosures with high human exposure. Regardless, considering the limitations 
in increasing enclosure size and reducing exposure to humans, regular exercise can 





Captive cheetahs at Smithsonian facilities show levels of stress greater than 
their captive counterparts at CCF in Namibia. These indicators of stress are associated 
with higher serum concentrations of the SAA protein, increasing the probability that 
they will develop AA amyloidosis during their lifetime. Until appropriate treatments 
become available that may control serum SAA protein concentrations, the best 
strategy to decreasing AA amyloidosis prevalence will be promoting captive 
population management practices that reduce stress, such as increasing enclosure size, 
or increasing opportunities for exercise where cheetahs are housed in small 
enclosures with high human exposure. Such practices could help re-establish proper 
immune system homeostasis and mitigate the overproduction of SAA protein, 
decreasing the probability of developing AA amyloidosis.  
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Chapter 5:  Summary of study results and the implications for 




Among the commercial animal industry, marker-assisted selection (MAS) is a 
movement towards using genetic data to make selection and breeding decisions that 
have been traditionally made using phenotypic records based on best linear unbiased 
prediction (BLUP; Henderson 1984). The use of MAS has historically been 
constrained by the limited availability of genomic information. With costs for whole 
genome sequencing and resequencing decreasing and the invention of novel SNP 
(single nucleotide polymorphism) discovering technologies, the genomic information 
required to apply marker-assisted selection in management practices is becoming 
much more feasible to acquire. Fernando and Grossman (1989) developed a model 
for BLUP that could incorporate the marker information into the genetic evaluation of 
individuals still accounting for fixed effects and phenotypic data. This model is even 
able to accommodate individuals who have missing or incomplete marker 
information.  
Traits that are generally targeted by commercial breeding programs have 
economic value, are quantitative in nature, and are affected by small gene effects 
from many loci, otherwise termed quantitative trait loci (QTL), and the influence of 




observations and the QTL. Variants (marker alleles) of the QTL that are significantly 
associated with favorable phenotypic values (and likely associated with a gene that 
controls the trait of interest) are targeted for selection. Individuals who carry these 
alleles are thus preferential breeders.  
MAS is variable in its success, mainly due to the unknown relationship 
between the marker alleles and the genes of interest. A marker located within the 
gene of interest yields the greatest success, particularly when the gene has a large 
effect on the trait, because association between the marker and the gene is perfect. 
Markers in linkage disequilibrium with the gene of interest show some success, but 
are limited by the quality of the data used to determine the statistical associations and 
the distance between the marker and the gene. Genetic improvement from MAS is 
also limited to the variance in the trait that is explained by the QTL. Important to note 
as well, is that individual markers or genes cannot be selected. Whole individuals are 
ultimately the unit for selection and positive effect alleles at one locus may be 
counter-balanced by negative effect alleles at another. The breeding value for an 
individual is thus determined by a sum of all the allele effects across all loci 
(Fernando and Grossman 1989). 
MAS can be used to increase the rate of genetic gain in commercially bred 
animal populations when compared to traditional selection methods (Meuwissen et al. 
2001). However, long term predictions of gain are dependent upon the number of 
alleles, the initial allele frequencies and the distribution of allele effects (Meuwissen 




generations of selection due to the breakdown of linkage-disequilibrium (Habier et al. 
2009, Meuwissen et al. 2001). 
When to use marker-assisted selection 
Marker-assisted selection is most effectively used when accuracy of selection 
is low using traditional methods. This occurs most frequently when heritability of a 
trait is low or the number of data points (phenotypic records obtainable) is low due to 
expense or availability. Relative efficiency of MAS is greatest when the heritability 
of the selected trait is low (Lande and Thompson 1990) because phenotypic 
information from the individual is less informative alone for genetic merit. Marker-
assisted selection increases selection accuracy in young animals, because selection 
decisions can be made before there is a record for the trait of interest (Calus et al. 
2008, Lande and Thompson 1990, Meuwissen and Goddard 1996). Earlier selection 
of individuals reduces the generation interval in a population, which further increases 
the rate of genetic gain obtained. Accuracy of selection can also be low for disease 
resistance-related traits (unobservable in most cases) and sex-limited traits (because 
records only exist for one sex). MAS provides the ability to select opposite sex 
individuals in the event of sex-limited traits. 
Role of MAS in captive breeding programs 
Marker-assisted selection in conservation breeding programs can play a 
similar role as it does in commercial breeding, but with a different purpose. MAS 
could be beneficial to conservation programs by increasing the effective size of small 
populations (Wang 2001) and decreasing inbreeding accumulation (Pedersen et al. 




individuals who have underrepresented genotypes (or haplotypes) to maintain genetic 
diversity in captivity (Ballou and Lacy 1995), particularly in populations where 
previous breeding has been highly skewed towards individuals who perform well in 
captivity (Ballou and Lacy 1995). Identification of marker alleles that are unique in 
an individual would make it a strong selection candidate to ensure representation of 
that genotype in the next generation.  
There are multiple strategies that exist today for breeders from zoos and other 
wildlife centers to utilize when making breeding decisions. The two most common 
strategies to date are maximum avoidance of inbreeding (MAI; Kimura and Crow 
1963) and minimizing mean kinship, defined as the average of the kinship 
coefficients between an individual and all other living individuals (MK; Ballou and 
Lacy 1995). MAI works by minimizing any further inbreeding accumulation in the 
population, without utilizing any historical pedigree information. MK works by 
minimizing the overall level of relationship among individuals in a population. MK 
does use historical pedigree information and is advantageous over MAI when there 
are unequal contributions of the initial founders to the current population 
(Montgomery et al. 1997). Minimizing mean kinship, while considering demographic 
constraints, as a breeding strategy appears to have been the most effective to date for 
retaining the greatest amount of founder genetic diversity (Ballou and Lacy 1995, 
Montgomery et al. 1997, Rodriguez-Clark 1999). However, whether this provides any 
fitness advantages or improves the probability of persistence for populations under 
natural selective pressures has yet to be determined (Montgomery et al. 1997, 




The use of genomic information can also give population managers a more 
accurate estimate of kinship between individuals and inbreeding accumulation, 
making both MAI and MK more effective strategies for conserving genetic diversity 
through captive breeding programs. One of the greatest benefits MAS can likely 
provide in conservation breeding is the ability to make selection decisions within 
families (among full siblings) whose genetic merit would otherwise appear equal. 
General criteria for the use of genotyping in non-model species includes of the 
ability to obtain high quality genotypes from small amounts or low quality DNA 
samples (Morin et al. 2004) and low cost and rapid ascertainment of sequence 
information per genome (Morin et al. 2004). If a species is threatened or endangered, 
there may be very few individuals to sample. Screening fewer individuals is going to 
find more markers with intermediate allele frequencies (ascertainment bias), which 
would not be selection target loci of interest when the goal is to identify and preserve 
rare or unique haplotypes. To detect SNPs of greater interest, candidate genes with 
known functions that influence fitness or fitness-related traits could be sequenced and 
analyzed for SNPs (Morin et al. 2004). SNPs closely linked to such genes are likely 
better candidates for genetic improvement through marker-assisted selection. The 
SNP in the putative NF-κB binding site of the SAA1A promoter in cheetahs is an 
example of a possible candidate.  
Relevance of the SAA1A-97delG SNP in the NF-κB binding site in SAA1A promoter in 
captive cheetah population management  
Before beginning this study, it was hypothesized that animals with the 




during inflammation and that this allele would be associated with a higher incidence 
of AA amyloidosis. If this relationship was true, the SNP in the putative NF-κB 
binding site within the promoter region of the SAA1A gene locus would be a 
potential target for MAS. MAS could be a beneficial component of the captive 
breeding program to decrease the prevalence of AA amyloidosis among captive 
cheetahs and promote a self-sustaining population.  
Based on the results of this study (Chapter 2), even though there was a 
significant decrease in the log10SAA protein concentration in serum as the number of 
copies of the SAA1A-97delG SNP increased, thus appearing to reduce the risk of 
developing AA amyloidosis in the presence of chronic or persistent inflammation, I 
cannot recommend this locus to be targeted for MAS in the captive North American 
cheetah population for the following reasons: (1) the SAA1A-97delG allele is already the 
more common allele in the captive North American cheetah population, thus selecting 
individuals with this allele would actually decrease the genetic diversity at this locus 
and this opposes the overall goals of the captive breeding program; and (2) there was 
no association found between the SNP and AA amyloidosis diagnosis in the captive 
North American cheetah population, therefore the differences in the log10SAA protein 
concentration observed between genotypes may not be relevant biologically in terms 





The role of proinflammatory cytokines (TNF-α, IL-1β, IL-6) in AA amyloidosis 
pathogenesis 
Almost 100% of captive cheetahs in North America have gastritis (a chronic 
inflammatory condition) to some degree (Munson 1993, Munson et al. 1999, Munson 
et al. 2005). However, the present study found proinflammatory cytokine 
concentrations to be highest and most variable among wild and “soft-release” 
cheetahs and lowest among the captive Smithsonian cheetahs. If one were to examine 
the Smithsonian population only, they may suggest that cheetahs are immune 
deficient, citing evidence for the lack of genetic variation in cheetahs, including a 
study that showed a lack of skin graft rejection among unrelated cheetahs (O’Brien et 
al. 1985). However, more recent studies have shown that the MHC class I α1 and α2, 
as well as MHC class II β1 domains are not monomorphic, with some amino acid 
differences located in sites important for antigen binding (Castro-Prieto et al. 2011). 
Therefore, cheetahs are not entirely immune-incompetent.  
One SCBI cheetah, 114681, did have high proinflammatory cytokine 
concentrations in the range of wild cheetahs, but was excluded from the analysis for 
being a significant outlier relative to the NZP-SCBI population. In addition, the 
PBMC stimulation experiment (Chapter 3) was successfully able to induce activation 
of and proinflammatory cytokine production from freshly isolated cheetah 
monocytes. Both of these results suggest that cheetahs are not immune-incompetent. 
Interesting to note is that the amount of cytokines produced in response to LPS 




suggest some individuals’ cells are more capable of responding to stimulus, though 
this effect may not be genetic because the three male cheetahs used in the experiment 
were full-sibling brothers.  It could be possible that “pre-treatment” in vivo of the 
monocytes with glucocorticoids could have made them less responsive, however the 
individual with the least responsive cells actually had the lowest concentration of 
cortisol in a serum sample drawn at the same time as the whole blood collection, so 
that does not appear to be the explanation. It is also possible that the number of cells 
remaining in culture after “washing” were not equal between animals. A cell-
concentration dependent effect was observed during this experiment within animals, 
so it would be logical to think the differences observed between individuals could, to 
some degree, be attributable to the same effect.  
In domestic cats, the production of cytokines decreases from youth to middle 
age then increases again in elderly animals (Paltrinieri 2008). There is not enough 
variability among the NZP-SCBI captive cheetahs to look for this type of effect; 
however, we do see a similar pattern among the captive cheetahs at CCF (Figure 5.1).  
Though not intuitive, the way that captive cheetahs are fed may be related to 
the amounts of circulating proinflammatory cytokines. Insulin is inhibitive to IL-1 
and IL-6 type cytokine responses (Baumann and Gauldie 1994). Most of the captive 
cheetahs at SCBI are fed once a day, but for those individuals being fed more than 
once a day, it is possible that more frequent releases of insulin may contribute to the 
lower concentrations of proinflammatory cytokines observed in these animals. 
Captive cheetahs at CCF are fed only once a day, 6 days per week and wild or “soft-






















and success of hunting efforts. It can be argued that if the captive cheetahs have 
elevated epinephrine due to stress that insulin secretion is inhibited (Norris 2007). 
However, elevated epinephrine also inhibits proinflammatory cytokine production, 
thus it is difficult to separate these effects and their influences on the differences in 
proinflammatory cytokines observed between populations. 
There are numerous studies that show various ways in which proinflammatory 
cytokine gene expression and protein production is inhibited by glucocorticoids, thus 
I believe the most likely explanation for this study’s results is dysregulation of the 
immune system and suppression of the production of proinflammatory cytokines in 
captive NZP-SCBI cheetahs due to chronic stress (discussed in more detail in Chapter 
4).  
Implications of inflammation for captive cheetah population management 
Previous studies have shown that all cheetahs diagnosed with amyloidosis also 
suffer from other significant chronic inflammatory diseases (Papendick et al. 1997) 
such that the high prevalence of AA amyloidosis among captive cheetahs is likely 
related to chronic inflammation. Unfortunately, this study was unable to get a clear 
picture of chronic inflammation among captive North American cheetahs based on a 
single blood sample from each individual and the measurement of just three 
cytokines, particularly when these cheetahs showed evidence of stress (elevated 
cortisol) that may be suppressing the production of proinflammatory cytokines. 
Further studies are required to understand the role of proinflammatory cytokines in 






The role of stress in AA amyloidosis pathogenesis 
 Based on this study, the most significant factor related to SAA protein 
concentration in serum and the probability of developing AA amyloidosis was stress: 
stress is measured as the baseline and/or average cortisol concentration in feces over 
time. The physiological changes that occur in response to acute stress are intended to 
increase the short-term survival of an organism, but when stress becomes chronic, 
these same changes can become detrimental. There is evidence for seasonal changes 
in glucocorticoids (GCs) due to changes in the allostatic load, or the animal’s 
requirements to survive (Busch and Hayward 2009). This, combined with an increase 
in acute stress events (hunting, injury, intra- or inter-specific conflicts), is the most 
likely explanation for the higher cortisol concentrations observed in wild cheetahs 
compared to captive CCF cheetahs in the same environment.  
 Hunting is one of the most fundamental behaviors observed in felid species, 
and when felids are put in captivity, they are deprived of the ability to hunt. Though 
this may protect them from the physical stress of hunting or getting injured, any 
physiological benefits associated with hunting (e.g. mental stimulation and exercise) 
are also lost. In this study, exercise was associated with a decrease in SAA protein 
concentrations in cheetahs kept in small enclosures with frequent human exposure. 
This suggests a physiological benefit of exercise among cheetahs in a zoological 
setting, perhaps simply by reducing stress, or a more complex scenario such as the 
activation of the sympathetic nervous system decreasing proinflammatory cytokines 




regularly, either on a lure system or by chasing the feeding truck. Therefore, exercise 
may partially explain the population differences observed in stress and/or SAA 
protein concentrations. Larger enclosures and low frequency of exposure to humans 
were also associated with lower SAA protein concentrations in serum.  
Implications of stress for captive cheetah population management 
Regardless of the mechanism behind the association of stress with higher 
SAA protein concentrations, it seems that measures should be taken to decrease stress 
whenever possible. This may mean limiting the number of times an individual is 
moved between facilities, since this is known to be associated with long-term 
increases in stress in cheetahs (Wells et al. 2004). For individuals that are identified 
as being particularly stressed, it may mean considering moving them to a facility 
where they will no longer be on exhibit to the public (decreasing exposure to 
humans), particularly if the animal has a breeding recommendation. Limiting the 
number of keepers that are taking care of the cheetahs on a daily basis may be another 
effective way to decrease stress associated with human interactions. 
Since cheetahs are known as the fastest land mammal, increasing the amount 
of exercise individuals are getting could be a really unique management strategy 
employed that may even improve the visitor experience at a zoo if exercising is done 
during business hours and the public has access to watch. A good example of this is 
the Cheetah Encounter Show at the Cincinnati Zoo. Cheetahs used in this program 





Other possible management considerations 
Dietary requirements 
 A recently published study by Liu et al. (2014) found that mice hepatocytes 
cultured in zinc deficient media stimulated with IL-6 and IL-1β produced 
significantly more SAA1 protein than cells cultured in zinc-sufficient media. The 
study illustrated that zinc deficiency results in more phosphorylation of IκB proteins, 
leading to their disassociation from the NF-κB transcription factor, subsequently 
allowing NF-κB to enter the nucleus and promote transcription of the SAA1 gene 
(Liu et al. 2014). Therefore, it is possible that captive cheetahs eating a zinc deficient 
diet may be predisposed to developing AA amyloidosis.  
Species specific dietary requirements for exotic feline species are not actually 
known. Diets fed to captive felids in Association of Zoos and Aquariums (AZA) 
accredited institutions meet the Association of American Feed Control Officials 
(AAFCO) criteria determined for domestic cats, as they are the closest model species 
for larger captive felids. It is possible that cheetahs are unique and have higher zinc 
requirements than domestic cats. Even so, captive diets seem to be over supplemented 
with zinc (Cheryl Morris and Michael Maslanka, personal communication), so this is 
likely not the driving force behind the high incidence of AA amyloidosis in captivity. 
Future studies may consider measuring serum concentrations of zinc to see if it is 
linked to the increases in SAA protein concentrations observed.  
Medical treatments  
Due to the positive, synergistic effect of GCs with cytokines in the induction 




Dowton 1994), administering glucocorticoids as a therapy for diseases characterized 
with chronic inflammation may have an undesirable or even harmful effect resulting 
in higher serum SAA concentrations. Therefore, it may not be appropriate for use in 
cheetahs. The benefit of GC treatment vs. the possibility of developing AA 
amyloidosis should be considered before treatment is given.  
A promising therapy using SAA-specific antisense oligonucleotides (ASO) 
has been shown to reduce SAA concentration in mice, particularly by facilitating a 
more rapid return to baseline after episodic bursts in SAA concentration (Kluve-
Beckerman et al. 2011).  SAA-specific ASOs were also shown to reduce amyloid 
deposition in treated mice in which amyloidosis was previously induced (Kluve-
Beckerman et al. 2011). Whether ASOs could be a therapy to treat systemic 
amyloidosis in either humans or cheetahs has yet to be investigated. 
The simplest answer to decreasing AA amyloidosis prevalence among captive 
cheetahs may simply be finding a way to control gastritis since AA amyloidosis is 
almost always associated with gastritis (Papendick et al. 1997). However, gastritis 
also appears to be linked to chronic stress in captive cheetahs, so controlling stress 
should always be emphasized.  
Conclusion 
 
 Controlling the amount of psychological stress imposed on cheetahs needs to 
be emphasized foremost in the management of captive cheetah populations because 
chronic stress is so intimately linked to decreased health in this species. In cases 




treatments may be found to be beneficial in decreasing SAA protein concentrations 
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Appendix I. Confirmation of SAA1A promoter specificity of 
F3A primer via nested vs. non-nested PCR.  
 
SAA1FFAM = 2nd round PCR product from nested PCR 
 
SAA1FFAMNOF3A = PCR product from SAA1F/SAA1R primers only. No 1st round 












































Appendix II. Complete list of fecal and serum samples collected 
from cheetahs. 






Captive North America NZP 113904 Female 11 43 Yes 
Captive North America SCBI 113906 Female 10 44 Yes 
Captive North America NZP 114193 Male 6 39 Yes 
Captive North America NZP 114194 Male 6 39 Yes 
Captive North America NZP 114195 Male 6 41 Yes 
Captive North America SCBI 114277 Female 7 39 Yes 
Captive North America SCBI 114382 Female 5 40 Yes 
Captive North America SCBI 114486 Female 8 50 Yes 
Captive North America SCBI 114539 Male 3 39 Yes 
Captive North America SCBI 114540 Male 3 38 Yes 
Captive North America SCBI 114541 Male 3 39 Yes 
Captive North America SCBI 114645 Male 1 43 Yes 
Captive North America SCBI 114680 Male 1 40 Yes 
Captive North America SCBI 114681 Female 1 40 Yes 
Captive North America SCBI 114682 Female 2 37 Yes 
Captive North America SCBI 114701 Male 8 37 Yes 
Captive North America SCBI 114702 Male 8 42 Yes 
Captive North America SCBI 114735 Male 1 36 Yes 
Captive North America SCBI 114736 Female 2 41 No 
Captive North America SCBI 114748 Female 8 50 Yes 
Captive North America SCBI 114799 Male 9 39 Yes 
Captive Namibia CCF 1119 Female 15 14 Yes 
Captive Namibia CCF 1203 Female 13 16 Yes 
Captive Namibia CCF 1204 Female 13 14 Yes 
Captive Namibia CCF 1206 Female 13 13 Yes 
Captive Namibia CCF 1233 Female 13 14 Yes 
Captive Namibia CCF 1237 Female 13 13 Yes 
Captive Namibia CCF 1340 Female 15 10 Yes 
Captive Namibia CCF 1355 Female 11 14 Yes 
Captive Namibia CCF 1380 Female 10 13 Yes 
Captive Namibia CCF 1444 Female 9 7 Yes 
Captive Namibia CCF 1493 Female 9 14 Yes 
Captive Namibia CCF 1510 Female 7 14 Yes 
Captive Namibia CCF 1511 Female 7 14 Yes 
Captive Namibia CCF 1512 Female 7 14 Yes 
Captive Namibia CCF 1513 Male 7 14 Yes 




Captive Namibia CCF 1515 Male 7 14 Yes 
Captive Namibia CCF 1516 Male 7 14 Yes 
Captive Namibia CCF 1517 Female 7 14 Yes 
Captive Namibia CCF 1518 Male 7 15 Yes 
Captive Namibia CCF 1560 Female 5 14 Yes 
Captive Namibia CCF 1565 Male 5 14 Yes 
Captive Namibia CCF 1578 Female 5 14 Yes 
Captive Namibia CCF 1600 Female 3 15 Yes 
Captive Namibia CCF 1601 Male 3 14 Yes 
Captive Namibia CCF 1602 Male 3 14 Yes 
Captive Namibia CCF 1603 Female 3 14 Yes 
Captive Namibia CCF 1607 Male 3 14 Yes 
Captive Namibia CCF 1616 Male 3 14 Yes 
Captive Namibia CCF 1627 Male 2 14 Yes 
Captive Namibia CCF 1632 Female 5 9 Yes 
Captive Namibia CCF 1640 Female 0 14 Yes 
Captive Namibia CCF 1641 Female 0 14 Yes 
Captive Namibia CCF 1642 Female 1 14 Yes 
Soft-Release Namibia Bellebenno 1243 Female 10 3 Yes 
Soft-Release Namibia Bellebenno 1348 Female 8 2 Yes 
Soft-Release Namibia Bellebenno 1349 Female 8 4 Yes 
Soft-Release Namibia Bellebenno 1351 Female 8 1 Yes 
Soft-Release Namibia Bellebenno 1513 Male 6 2 No 
Soft-Release Namibia Bellebenno 1515 Male 6 1 No 
Soft-Release Namibia Bellebenno 1516 Male 6 1 No 
Soft-Release Namibia Bellebenno 1518 Male 6 1 No 
Soft-Release Namibia Bellebenno 1539 Male 6 6 No 
Soft-Release Namibia Bellebenno 1540 Male 4 5 No 
Soft-Release Namibia Bellebenno 1545 Male 3 5 No 
Soft-Release Namibia Bellebenno 1560 Female 4 1 Yes 
Soft-Release Namibia Bellebenno 1561 Male 3 9 No 
Soft-Release Namibia Bellebenno 1578 Female 4 1 Yes 
Wild Namibia Wild 1537 Male 6 9 Yes 
Wild Namibia Wild 1538 Male 6 1 Yes 
Wild Namibia Wild 1542 Male 6 15 Yes 
Wild Namibia Wild 1543 Male 6 15 Yes 
Wild Namibia Wild pop169 Male unk 7 No 
Wild Namibia Wild pop170 Male unk 7 No 
Wild Namibia Wild Scat1161 Male unk 10 No 
NZP = Smithsonian National Zoological Park, SCBI = Smithsonian Conservation 
Biology Institute, CCF = Cheetah Conservation Fund, Bellebenno = Soft-release 
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